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Abstract:
Food manufacturers are under increasing pressure to limit the amount of 
free sugars in their products.  Many have reformulated products to 
replace sucrose, glucose and fructose with alternative sweeteners, but 
some of these have been associated with additional health concerns. 
 Rare sugars are “monosaccharides and their derivatives that hardly 
exist in nature”, and there is increasing evidence that they could have 
health benefits.  This review aimed to scope the existing literature in 
order to identify the most commonly researched rare sugars, to ascertain 
their proposed health benefits, mechanisms of action and potential uses, 
and to highlight knowledge gaps.  A process of iterative database 
searching identified 55 relevant articles.  The reported effects of rare 
sugars were noted, along with details of the research methodologies 
conducted.  Our results indicated that the most common rare sugars 
investigated are D-psicose and D-tagatose, with the potential health 
benefits divided into three topics: glycaemic control, body composition 
and cardiovascular disease.  All the rare sugars investigated have the 
potential to suppress postprandial elevation of blood glucose and 
improve glycaemic control in both human and animal models.  Some 
animal studies have suggested that certain rare sugars may also 
improve lipid profiles, alter the gut microbiome and reduce pro-
inflammatory cytokine expression.  The present review demonstrates 
that rare sugars could play a role in reducing the development of 
obesity, type 2 diabetes, and/or cardiovascular disease.  However, 
understanding of the mechanisms by which rare sugars may exert their 
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1 Abstract
2 Food manufacturers are under increasing pressure to limit the amount of free sugars in their 
3 products.  Many have reformulated products to replace sucrose, glucose and fructose with 
4 alternative sweeteners, but some of these have been associated with additional health concerns.  
5 Rare sugars are “monosaccharides and their derivatives that hardly exist in nature”, and there 
6 is increasing evidence that they could have health benefits.  This review aimed to scope the 
7 existing literature in order to identify the most commonly researched rare sugars, to ascertain 
8 their proposed health benefits, mechanisms of action and potential uses, and to highlight 
9 knowledge gaps.  A process of iterative database searching identified 55 relevant articles.  The 
10 reported effects of rare sugars were noted, along with details of the research methodologies 
11 conducted.  Our results indicated that the most common rare sugars investigated are D-psicose 
12 and D-tagatose, with the potential health benefits divided into three topics: glycaemic control, 
13 body composition and cardiovascular disease.  All the rare sugars investigated have the potential 
14 to suppress postprandial elevation of blood glucose and improve glycaemic control in both human 
15 and animal models.  Some animal studies have suggested that certain rare sugars may also 
16 improve lipid profiles, alter the gut microbiome and reduce pro-inflammatory cytokine 
17 expression.  The present review demonstrates that rare sugars could play a role in reducing the 
18 development of obesity, type 2 diabetes, and/or cardiovascular disease.  However, 
19 understanding of the mechanisms by which rare sugars may exert their effects is limited, and 
20 their effectiveness when used in reformulated products is unknown.   
Page 4 of 64
Cambridge University Press
British Journal of Nutrition
For Review Only
21 Introduction
22 There is increasing concern over the excess intake of metabolizable free sugars, which is 
23 associated with obesity and increased risk of non-communicable diseases(1-3).  Many food 
24 manufacturers are reformulating products to replace sucrose, glucose or fructose with dietary 
25 fibres, polyols or high-intensity sweeteners, but alternative sweeteners may be associated with 
26 health concerns such as appetite dysregulation and glucose intolerance(4).  Rare sugars, defined 
27 by the International Society of Rare Sugars as “monosaccharides and their derivatives that 
28 hardly exist in nature”(5), have attracted increasing interest as a result of recent advances in 
29 their commercial-scale biosynthesis(6; 7).  Rare sugars are low-calorie monosaccharides with 
30 similar sweetness to that of sucrose(6).  The rare sugars D-psicose (PSI, also known as allulose) 
31 and D-tagatose (TAG) have ‘generally recognised as safe’ (GRAS) status(8; 9).  Both are already 
32 in use in products such as biscuits, chocolate, jam(10), protein bars, soft drinks(11) and in 
33 commercial sweetener blends(12) in parts of Europe, Asia and the USA.    Rare sugars have the 
34 advantage that, unlike high-intensity sweeteners, they can replace both the physical bulk and 
35 some of the sweetness of sucrose. They can therefore be used as a direct replacement for a 
36 significant portion of free sugars(13-15), allowing the production of confectionery with lower energy 
37 content.  PSI in particular is an attractive option for food manufacturers as it is exempted from 
38 ‘total sugars’ and ‘added sugars’ figures on nutrition labelling in the USA(11).  
39 The potential benefits of rare sugars go beyond simply replacing sucrose to reduce calorie intake.  
40 Research into the potential uses of rare sugars has been ongoing since the late 1990s, primarily 
41 in East Asia, with minimal research activity in the UK.  They have been shown to have a range 
42 of beneficial biological functions(6), some of which could help to alleviate problems associated 
43 with the high consumption of free sugars.  The biological actions of various rare sugars suggest 
44 they could contribute towards health improvements in a range of interlinked conditions, including 
45 obesity, type 2 diabetes (T2D) and cardiovascular disease (CVD)(6; 15; 16).  Rare sugars therefore 
46 have the potential to be used not only to replace sucrose in product reformulation, but also as 
47 functional ingredients with health promoting properties.  Functional foods are foods or drinks 
48 which can have health benefits beyond their basic nutritional value(17).  In order for health claims 
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49 to be made about a food or ingredient, there must be robust evidence that it reaches its site of 
50 action, beneficially affects a physical function or biomarker, and has a direct impact on health 
51 status when consumed as part of a normal diet(17).  Research on rare sugars is in its early stages, 
52 and the evidence that would be required to make health claims is not yet available.  More 
53 research is necessary before it can be claimed that rare sugars have health benefits in the 
54 general population.  
55 The majority of research to date has focussed on measuring a limited range of outcomes, (for 
56 example body composition, glycated haemoglobin (HbA1c) levels or short-term glycaemic 
57 response) and the biological mechanisms underlying these outcomes are not yet clear.  While 
58 there are several commercially available food products containing rare sugars(10; 11), there has 
59 been no research into the possible health benefits of these products.  A detailed examination of 
60 the existing literature could help to explain mechanisms of action and highlight areas where 
61 further research is needed.  Existing reviews on rare sugars have either focussed on a single 
62 sugar(9; 15; 16; 18; 19) or are broad summaries of potential uses, with little focus on mechanisms of 
63 action(6; 20).  The purpose of this scoping review is to provide an updated, comprehensive 
64 summary of the research into the potential health benefits of rare sugar consumption.  The 
65 review identifies the most commonly researched rare sugars, explores their potential health 
66 benefits, mechanisms of action and possible uses, and highlights gaps in the evidence.  
67 Understanding the scope of the current evidence base and its limitations is critical to improving 
68 the design and implementation of future studies.  
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69 Methods
70 A scoping review differs from a systematic review, in that it aims to rapidly map the key concepts 
71 underpinning a research area.  This scoping review aimed to identify primary research into the 
72 health benefits of the consumption of rare sugars, and employed the framework set out by 
73 Arksey and O'Malley(21).  While the objectives and methods were specified in advance, search 
74 terms and inclusion criteria were adapted during the process as the scope of the literature was 
75 identified.
76 Review Questions
77 This review seeks to answer the following questions:
78 1) Which rare sugars have been researched?
79 2) What are their known effects when consumed orally?   
80 3) What are the mechanisms of action for these effects?
81 4) What are the proposed health benefits of rare sugars?
82 5) How might rare sugars be used to provide these health benefits?
83 6) What are the priorities for future research into rare sugars?
84 Identifying Relevant Studies
85 In order to test possible search terms, gain an overview of the literature and define the key 
86 concepts, a limited search of the literature was performed.  The search term ‘rare sugar AND 
87 (uses OR nutrition OR health)’ was used in a search of Scopus.  The titles and abstracts of the 
88 articles were scanned and several recent reviews were read in full(6; 16; 22), allowing the 
89 identification of key concepts: the most commonly-researched rare sugars, and broad areas of 
90 relevant research.  These concepts were used to develop a search matrix for a systematic 
91 literature search (table S1), and to refine inclusion and exclusion criteria. 
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92 For the scoping review, all searches were performed in three databases (Scopus, PubMed and 
93 Web of Science) using identical search terms.  The most recent searches were completed on 5th 
94 January 2021.  Following title and abstract screening, the reference lists of relevant articles were 
95 searched to identify additional studies.
96 Study Selection
97 Inclusion and exclusion criteria
98 Preliminary literature searching revealed a wide range of uses for rare sugars(6).  While many of 
99 these are health-related, some involve the use of rare sugars in an industrial, pharmaceutical, 
100 or medical context.  This review focuses on the health benefits of rare sugars in nutrition, 
101 therefore only includes studies where rare sugars have been administered orally in vivo, in 
102 humans or mammals.  A significant milestone in rare sugars research was the discovery in 2004 
103 of enzymatic methods by which rare sugars could be produced on an industrial scale(23).  This 
104 resulted in an increase in relevant research studies, particularly human trials.  In order to rapidly 
105 identify the most relevant research, this review as therefore limited to articles published after 
106 1st January 2004.  Where relevant articles were unavailable in English, their abstracts were still 
107 included.  
108 This review includes: 
109 - Primary, in vivo research in humans or mammals in which rare sugars were administered orally.  
110 - Studies published after 1st January 2004.  
111 Studies were excluded if: 
112 - The type or quantity of rare sugar were unclear (e.g. those using plant extracts)
113 - The rare sugar was not administered orally (e.g. solution injected or used in surgical procedures).  
114 Study Screening
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115 The process of article screening is summarised in Figure 1.  Following database searching and 
116 removal of duplicates, title screening and abstract screening were carried out using the defined 
117 inclusion and exclusion criteria stated above. 
118 Charting the Data 
119 Included articles were read in full and data extracted.  Microsoft Excel spreadsheets were used 
120 to allow methodical collection of available data, including the location, animal model or study 
121 population used, study design, rare sugar used, timescale, dosage, outcome measures and 
122 significant findings.  Separate tables were used to record data from animal and human trials 
123 (table S2a and table S2b, respectively).  As a scoping review aims to rapidly identify the 
124 parameters and gaps in a research area, quality of research is not a priority(24), therefore no 
125 systematic quality assurance was conducted and data from abstracts were included where full 
126 methods were not available.  
127 Collating, Summarising and Reporting the Results  
128 Study characteristics and available data were tabulated.  A mapping diagram (Figure 2) was 
129 created to summarise the proposed health benefits described in the literature and their inter-
130 relationships.  Where several studies had similar methodology, additional tables were created to 
131 enable comparison of their methods, outcomes, and effect sizes.
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132 Results 
133 The outcomes of literature searching and article screening are summarised in figure 1.  A total 
134 of 55 articles were included in this review (see tables S2a and S2b).  The rare sugars identified 
135 as being most relevant from the included articles were PSI (also referred to as allulose), TAG, 
136 D-sorbose (SOR), D-allose (ALL) and rare sugar syrup (RSS, a syrup containing glucose and 
137 fructose along with around 5% PSI and small quantities of other rare sugars, which can be 
138 economically produced by isomerization of high fructose corn syrup (HFCS) under alkaline 
139 conditions).  PSI, TAG and RSS are the most commonly researched rare sugars, and the only 
140 ones to have been used in human trials.  There has been relatively little research into the health 
141 benefits of SOR, although some animal studies suggest it has the potential to improve glycaemic 
142 control(25; 26).  Much of the research involving ALL uses the compound in a pharmaceutical context 
143 (injected intravenously or as an antioxidant in irrigation fluid during surgery) and, therefore, is 
144 excluded from this review.  There is limited research into the use of ALL as a dietary supplement, 
145 but one study in mice indicates that it has potential to improve fatty liver disease(27).
146 The reported in vivo effects of rare sugar consumption in humans included improved glycaemic 
147 control(28-39), reductions in body weight(36-39) and body fat(36; 39), and reduced low-density 
148 lipoprotein (LDL)-cholesterol and total cholesterol(40).  Similar effects were reported in animal 
149 studies.  Additionally there is evidence from animal trials that rare sugar intake may also reduce 
150 hepatic lipid accumulation(27; 41-46), alter the gut microbiome(44; 45; 47) and improve 
151 inflammatory(45; 47) and oxidative status(48-50).  Therefore, results on the impact of PSI, TAG, RSS, 
152 SOR and ALL on these outcomes (glycaemic control, body weight and body fat, lipid metabolism, 
153 hepatic lipid accumulation and gut microbiome) will be presented.  The effect of rare sugar 
154 consumption on appetite in humans has been monitored in some studies, with inconclusive 
155 results(51-53).  Table 1 summarises the key effects of rare sugar consumption as reported in the 
156 studies included in this review(54).  Taken as a whole, the evidence suggests that rare sugars 
157 may have the potential to improve or reduce the risk of obesity, T2D, CVD and fatty liver disease.  
158 The mapping diagram shown in figure 2 summarises how these interlinked conditions could be 
159 affected by rare sugar consumption.  Importantly, the diagram highlights that the effect of 
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160 lowering postprandial glucose levels may lead to multiple health benefits.  However, the majority 
161 of the evidence to date is from animal studies, and the mechanisms of action of the rare sugars 
162 are not understood.  The extent to which rare sugars can affect pathways that lead to the 
163 alleviating of disease states is unclear.  
164 Rare sugars and glycaemic control
165 There is evidence from human trials that both PSI and TAG, when consumed with a carbohydrate 
166 load, can reduce the resulting elevation in blood glucose in people with hyperglycaemia (28; 29; 33) 
167 (Table 2).  Most of these studies involved a control group consuming the same carbohydrate 
168 load, so the effect can be attributed to the rare sugar rather than a simple decrease in 
169 carbohydrate intake.  It should be noted that the reduction in the incremental area under the 
170 curve (iAUC) for glucose was relatively small (4-11% with PSI, 4% with TAG) compared to the 
171 effects of oral hypoglycaemic agents(55).
172 In studies where PSI(28; 56; 57) or TAG(33; 52) were consumed by healthy volunteers, no significant 
173 reductions in the iAUC for glucose were observed, although Kimura et al.(57) reported significantly 
174 lower blood glucose at 90 minutes after PSI was consumed before a standard meal.  Some 
175 studies did report significant reductions in the postprandial elevation of blood glucose (PEBG) 
176 with PSI(30) or RSS(31; 34) consumption in healthy volunteers, but in these studies the 
177 experimental groups consumed reduced carbohydrate loads compared to control groups.  The 
178 effects of SOR and ALL on glycaemic response have not been studied in humans, but one study 
179 in Wistar rats(25) reported a reduction in peak blood glucose concentration when SOR was given 
180 alongside a sucrose load.  
181 The effect of longer-term rare sugar consumption on glycaemic control has also been 
182 investigated, with inconsistent results.  Three studies examined the long-term effects of TAG in 
183 subjects with T2D(37; 38; 40)  Of these, two found small but significant decreases in HbA1c after 12 
184 months of regular TAG consumption (38; 40).  One study(36) investigated the effect of longer-term 
185 PSI consumption on glycaemic control in overweight individuals, and found no significant change 
186 in fasting blood glucose or HbA1c after 12 weeks.
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187 The animal studies included in this review highlight the different effects of rare sugars on long-
188 term glycaemic control in different animal models.  Four studies investigated the effect of PSI 
189 consumption in animal models of metabolic syndrome (db/db mice(58) or Otsuka Long-Evans 
190 Tokushima Fatty (OLETF) rats(43; 59; 60)), and all found significantly reduced plasma glucose with 
191 PSI compared to control groups.  A further 6 studies induced obesity and hyperglycaemia in 
192 wild-type animals by feeding high-sucrose or high-fat diets.  Of these, three found no significant 
193 differences in blood glucose or insulin with PSI(61; 62) or RSS(63) feeding. Reductions in fasting 
194 blood glucose were reported in two studies feeding PSI to mice with diet-induced obesity 
195 (DIO)(41; 42), and Pongkan et al.(64), found significant reductions in fasting insulin levels and 
196 insulin resistance when PSI was fed to obese Wistar rats.  Of the four studies in which there was 
197 no metabolic disorder, two reported a reduction in insulin levels with PSI(65) or RSS(66), with Iida 
198 et al. also reporting reduced fasting blood glucose(66).  The included animal studies using ALL(27; 
199 67), SOR(26; 68) and TAG(68-70) found no significant difference in blood glucose, although Yamada 
200 et al.(26) reported a reduction in non-fasting serum insulin levels after 4 weeks of SOR feeding.  
201 The effect of rare sugar consumption on body weight and body fat
202 Of the 27 animal studies where rare sugars were fed as part of the diet (typically 2-5% for PSI, 
203 RSS, ALL or SOR, 30% for TAG) or in drinking water (1-2% solution) for periods of 4 weeks or 
204 more, 22 studies found significant reductions in body weight with rare sugar consumption (see 
205 table 1).  In 18 of the studies, where adipose tissue mass was an outcome measure, significant 
206 reductions were reported in 17 studies (41-46; 48; 49; 59; 62; 63; 66; 71-74).  Many of these studies were 
207 designed to reduce or eliminate the effect of differences in caloric intake, either using a paired-
208 feeding approach or feeding isocaloric diets and carefully monitoring feed intake, but in some 
209 cases there was a calorie deficit in rare-sugar-fed animals.  
210 Although few long-term clinical trials have been conducted, two trials in healthy adults found 
211 reductions in body mass index (BMI) and body fat percentage (BFP) when drinks containing 
212 PSI(36) or RSS(39) were consumed regularly over 12 weeks.  Han et al.(36) reported modest but 
213 significant reductions in BMI (-0.38 kg/m2) and BFP (-0.74%) in subjects consuming 14g PSI 
214 per day, with significant differences compared to a sucralose control group in which these 
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215 parameters were unchanged.  Similarly, Hayashi et al.(39) found significant reductions in body 
216 weight (-1.85kg), BMI (-0.68 kg/m2) and BFP (-1.72%) in subjects consuming 30g RSS per day, 
217 while no significant changes in these parameters were seen in control groups consuming 
218 isocaloric drinks containing 28g HFCS.  In each of these studies food intake was recorded using 
219 24 hour recalls(36) or 3-day food diaries(39), and no significant differences between groups were 
220 reported.  Of three studies(37; 38; 40) where TAG was given regularly to adults with T2D, two found 
221 significant decreases in body weight from baseline, although neither of these studies had a 
222 control group(37; 38).  A large phase 3 clinical trial using the same dosing regimen (15g TAG three 
223 times daily before meals) found no significant differences in body weight between the TAG group 
224 and the control group who consumed a sucralose placebo(40).  None of the clinical trials using 
225 TAG reported food intake during the treatment period, so the potential contribution of calorie 
226 reduction and the effect of TAG on appetite are not known.  
227 Some of the animal studies in this review reported that PSI consumption resulted in decreased 
228 food intake(43; 51; 60; 66), indicating a potential effect of PSI on appetite, although in most of the 
229 animal studies there was no significant difference in food intake.    
230  Only one of the clinical trials in this review reported on differences in appetite with rare sugar 
231 consumption, and this was in the context of a study of gastrointestinal tolerance.  Participants 
232 were given gradually increasing doses of 0.2-1g PSI per kg body weight, with gradually 
233 increasing daily frequency, over 1 week to find the maximum daily dose for regular ingestion.  
234 Diminished appetite, as one of a range of reported adverse effects, was self-reported by two of 
235 the 19 participants on day 8, after consuming the highest dose of 1g PSI per kg body weight(75).  
236 Rare sugar consumption and lipid metabolism
237 Research methodologies used in animal studies include the measurement of plasma, hepatic and 
238 faecal triglycerides, cholesterol, and free fatty acids, as well as the expression and activities of 
239 enzymes involved in lipid metabolism.  Of the 25 studies where blood lipids were measured, 17 
240 used animal models of obesity (leptin deficient ob/ob mice or animals with DIO).  The reported 
241 effects of rare sugar consumption on lipid metabolism are contradictory: of all the animal studies 
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242 measuring plasma lipids, only 13 found overall beneficial effects of rare sugar consumption 
243 (reduction in plasma triglyceride or total cholesterol, or increased ratio of high-density 
244 lipoprotein (HDL) to LDL cholesterol).  Two of these were in Wistar rats without obesity(49; 76), 
245 although in both of these studies the diet of the PSI-fed rats was lower in energy than that of 
246 the control group.  Nine studies reported reduced LDL cholesterol or non-HDL cholesterol with 
247 PSI consumption(42; 44; 45; 49; 60-62; 71; 76), and in four of these studies the HDL:LDL cholesterol ratio 
248 was increased(42; 45; 61; 71).  However three studies found no significant effects of PSI on plasma 
249 cholesterol(41; 58; 64), while two reported increased plasma total cholesterol and LDL cholesterol 
250 with PSI(72) or TAG(70) administration.  It should be noted that all but one of these studies were 
251 carried out in rat or mouse models, in which cholesterol metabolism differs significantly from 
252 that of humans(61).  Kanasaki et al.(61) conducted a study in which PSI was fed to Syrian hamsters 
253 as part of a high fat diet over 8 weeks, and found no significant differences in plasma total 
254 cholesterol, although the HDL:LDL cholesterol ratio was increased.  
255 There is more consensus in the reported effects of rare sugars on lipid metabolism enzyme 
256 activity.  In general, PSI consumption tends to increase the activity of enzymes involved in β-
257 oxidation of lipids and decrease the activity of enzymes involved in lipogenesis (Table 3).  For 
258 example Do et al.(41) fed isoenergetic high fat diets with or without 5% PSI supplementation to 
259 mice for 8 weeks, and found that the livers of PSI-fed mice had reduced activity of phosphatidate 
260 phosphatase and glucose-6-phosphate dehydrogenase and increased activity of carnitine 
261 palmitoyltransferase 1.  In several studies, the observed changes in enzyme activity were 
262 accompanied by reductions in adipose tissue weight(41; 48; 71; 73), although in two shorter studies 
263 the reductions did not reach significance(65; 68).  Interestingly when Nagata et al.(68) compared 
264 the effects of 3% PSI, TAG and SOR in the diets of rats, they found that lipid metabolism enzymes 
265 were affected differently by the different rare sugars, for example the activity of fatty acid 
266 synthase was decreased in PSI-fed rats but increased in the TAG-fed group.  
267 Rare sugars and hepatic lipid accumulation
268 Although there are conflicting results concerning the effects of rare sugars on hepatic triglyceride 
269 and cholesterol content, there appears to be a consistent protective effect against hepatic lipid 
Page 14 of 64
Cambridge University Press
British Journal of Nutrition
For Review Only
270 accumulation with rare sugar consumption.  All eight of the animal studies in which hepatic lipid 
271 was measured found that rare sugar consumption dramatically reduced lipid accumulation.  In 
272 these studies, PSI(41-46; 49) or ALL(27) were fed to genetically obese or DIO animals and, while 
273 obese control groups developed hepatic fibrosis or ballooning degeneration, the livers of PSI-fed 
274 animals were found to be similar to non-obese controls(43-46).  
275 Rare sugars and the gut microbiome
276 Two recent papers by Han et al.(44; 45) explored the effects of PSI consumption on the gut 
277 microbiome, as a possible mechanism for its observed anti-diabetic effects.  In these studies PSI 
278 was fed as 5% of a high-fat diet to mice, with control groups pair-fed isocaloric high-fat diets.  
279 As well as reduced adipose tissue mass, serum lipids and hepatic lipids, these studies reported 
280 improved microbiome diversity; the microbiota of mice fed PSI with a high-fat diet was similar 
281 to that of mice fed a normal diet.  TAG, too, has been found to be beneficial for gut microbiota 
282 in mice with induced colitis: in a study by Son et al.(47), TAG (25mg), Lactobacillus rhamnosus 
283 (109cfu) or a combination of the two treatments were administered every other day by oral 
284 gavage, with a control group given saline.  Symptoms of colitis were reduced in TAG-fed groups, 
285 and synergistic effects were observed when TAG was fed alongside probiotics.  There were 
286 significant reductions in the proinflammatory cytokines interleukin (IL)-6 and IL-10 with both 
287 TAG and Lactobacillus alone, and additionally a reduction in tumour necrosis factor α (TNFα) with 
288 combination treatment.  
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289 Discussion
290 This scoping review found that there is evidence, primarily from animal trials, for beneficial 
291 effects of dietary PSI consumption, particularly anti-hyperglycaemic and hypolipidemic effects.  
292 PSI, therefore, could be a useful alternative for free sugars and assist with prevention strategies 
293 for obesity and T2D.  However, evidence from human trials is limited and research gaps remain.  
294 The actions of other rare sugars are less well-researched, but TAG has potential beneficial effects 
295 in the regulation of blood glucose.  The mapping diagram (Figure 2) illustrates how the known 
296 actions of rare sugars could contribute to important health benefits linked to obesity, T2D and 
297 CVD.  The majority of the studies reporting beneficial effects have involved animal models of 
298 metabolic disorders, or human subjects with hyperglycaemia, obesity or T2D (see Table 1).  The 
299 potential health benefits of rare sugars as part of an ongoing normal diet in healthy individuals 
300 are unclear.  
301 Unpacking the mechanisms of action of rare sugars
302 As outlined in figure 2, the observed in vivo effects of rare sugars are extensively interlinked.  
303 The reported effects of rare sugar intake could provide health benefits related to obesity, T2D, 
304 CVD and non-alcoholic fatty liver disease (NAFLD), but the precise mechanisms by which rare 
305 sugars exert their effects are not yet understood.  Potential mechanisms of action include 
306 improvements in glycaemic control, altered lipid metabolism, reduced appetite, reduced 
307 inflammation and improvements in the gut microbiome.  These factors will be discussed in the 
308 following sections.  
309 The wide range of study types and methods used in researching rare sugars has resulted in some 
310 gaps in our understanding of their mechanisms of action, for example where one sugar has been 
311 shown to influence an outcome, biomarker, pathway, or gene, which may not have been 
312 investigated using other rare sugars.  An understanding of the mechanisms of action is important 
313 when considering effects in different populations, and possible synergistic effects in vivo.  
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314 Glycaemic control: alteration in carbohydrate absorption and metabolism
315 As summarised in table 2, PSI and TAG have both been shown to reduce the elevation in blood 
316 glucose when given before or alongside a carbohydrate load.  There have been several suggested 
317 mechanisms for this effect, including reduced digestion and absorption of dietary carbohydrates, 
318 enhanced glucose uptake from the plasma, and stimulation of insulin secretion.  
319 SOR and TAG have both been found to inhibit sucrase and maltase enzymes from rat 
320 intestines(25), suggesting that reduced breakdown of disaccharides could be a mechanism by 
321 which rare sugars suppress PEBG.  However it does not fully account for the reduction in PEBG 
322 when rare sugars are given with a carbohydrate load composed entirely of glucose, as observed 
323 by Noronha et al. (29) and in several animal studies (43; 58-60).  It is clear that other mechanisms 
324 of action also play a part.  
325 Around 70% of ingested PSI is absorbed in the small intestine(60).  While glucose is transported 
326 largely by the sodium-glucose linked transporter (SGLT)1, both fructose and PSI enter 
327 enterocytes via the glucose transporter (GLUT)5.  Efflux from enterocytes for all three 
328 monosaccharides involves the GLUT2 transporter(77).  This raises the possibility that PSI could 
329 reduce the absorption of both glucose and fructose by competition for sugar transporters.  
330 Indeed, TAG has been shown to reduce fructose absorption by 26% over 60 minutes when 
331 administered to rats alongside equal quantities of fructose(78).  It would be useful to determine 
332 the transport pathways of each rare sugar, and the extent to which they can slow the transport 
333 of fructose and glucose.
334 A further potential mechanism for the suppression of PEBG is through enhanced glucokinase 
335 (GK) translocation.  GK catalyses the first step in the metabolism of glucose for the synthesis of 
336 glycogen and triacylglycerides, and is, therefore, critical in hepatic glucose metabolism.  It is 
337 regulated by transcriptional changes and by translocation from the nucleus to the cytoplasm in 
338 the fed state(79).  This translocation of GK has been shown to be lower in hyperglycaemic or 
339 diabetic animal models, such as OLETF rats(59).  The translocation of GK was enhanced in both 
340 OLETF rats(43) and non-diabetic Wistar rats(74) fed PSI.  An increase in translocation of GK to the 
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341 cytoplasm increases hepatic glucose uptake and contributes to better short-term regulation of 
342 blood glucose(79).   
343 It is possible that the reduced PEBG observed with rare sugar administration is related to 
344 increased insulin secretion, stimulated by incretin hormones.  These hormones, for example 
345 glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP), are released in response to 
346 the presence of nutrients in the duodenum, and enhance the glucose-stimulated release of 
347 insulin from the pancreatic islets.  One study in mice found that oral PSI administration 
348 stimulated GLP-1 release, leading to increased plasma insulin and reduced plasma glucose after 
349 intraperitoneal glucose injection(51).  Evidence from human trials, however, does not support this 
350 mechanism of action.  One study in healthy volunteers reported that TAG stimulated GLP-1 
351 release, but this did not lead to significant differences in blood glucose or insulin after a meal(52).  
352 Additionally, several studies in humans have demonstrated that PSI(29; 57), TAG(33) or RSS(31; 34) 
353 consumption can reduce the iAUC for glucose following a carbohydrate load, but with no 
354 significant effect on plasma insulin.  None of these trials reported measurements of incretin 
355 hormone levels.  Insulin and incretin hormones play a vital role in glycaemic control, and the 
356 effect of rare sugar intake on insulin and incretin release in humans requires further 
357 investigation.  
358 The relative contribution of these mechanisms in vivo is unknown, and may be different for 
359 different rare sugars.  Postprandial blood glucose shows high inter-individual variation(56) and is 
360 affected by the action of insulin, glucagon and gut peptides, so the efficacy of rare sugars in 
361 suppressing PEBG is likely to vary between different animal species or human study participants.  
362 Future studies should aim to recruit sufficient participants to overcome the effects of inter-
363 individual variation, and should measure not only blood glucose but also insulin and incretin 
364 hormone levels following the ingestion of rare sugars.  Such studies should also trial the intake 
365 of rare sugars in food products, similar to those currently marketed, to ascertain whether 
366 significant differences in postprandial glycaemic response are observed compared to a standard 
367 product.  
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368 While regular TAG consumption has been shown to reduce HbA1c(38; 40), regular PSI consumption 
369 showed no significant effects on glycaemic control(36).  The factors affecting long-term glycaemic 
370 control are complex, and research in humans is complicated by changes in treatment regimes in 
371 subjects with T2D(38).  The HbA1c measurement commonly used in diabetes management 
372 reflects average plasma glucose over the previous 8-12 weeks, but does not take into account 
373 glycaemic variation during that time(80).  PSI and TAG can both reduce PEBG (see Table 2), so it 
374 is possible that dietary PSI or TAG could reduce damaging episodes of both hypo- and 
375 hyperglycaemia without significantly reducing HbA1c measurements.  Further long-term, large 
376 scale studies are necessary to evaluate this, potentially using markers of short-term glycaemic 
377 control such as 1,5-anhydroglucitol(81).  
378 Alterations in lipid metabolism
379 One consistently observed in vivo effect of rare sugar consumption, in both animals and humans, 
380 is a reduction in BFP and adipose tissue weight(36; 39; 41-46; 48; 49; 59; 62; 63; 66; 71-74).  Several animal 
381 studies have also reported a protective effect of rare sugars against the hepatic steatosis that 
382 results from a high-fat diet(27; 41-43; 45; 46; 49; 82).  The effects of rare sugars on serum and liver 
383 lipids are less consistent, and the precise mechanisms for the hypolipidemic effects of rare sugars 
384 are not well understood.  
385 As shown in table 3, the intake of rare sugars appears to reduce the activity of lipogenic enzymes 
386 and increase the activity of those involved in β-oxidation.  These changes are a plausible 
387 mechanism for the reduction in adipose tissue mass or BFP observed with regular rare sugar 
388 intake.  Additionally, several studies observed significant reductions in the activity of enzymes 
389 involved in lipogenesis in the liver as a result of PSI feeding (Table 3).  These changes, as well 
390 as contributing to reductions in hepatic lipid accumulation, could also affect plasma lipid profiles.  
391 An increase in the activity of hepatic lipase in serum and liver, for example, could contribute to 
392 the reduction in plasma triglyceride observed in several studies(41; 42; 48; 71).
393 Lipid metabolism is affected by blood glucose concentration, via both insulin-dependent and 
394 insulin-independent pathways(83).  Figure 3 outlines some of the pathways of fatty acid 
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395 metabolism in the liver and adipose tissue, showing potential mechanisms by which PSI could 
396 reduce lipid accumulation.  Importantly, PSI appears to oppose the effect of insulin on several 
397 enzymes and pathways involved in lipid metabolism.  A key question to be addressed is whether 
398 the observed changes in enzyme activity, and the resulting reduction in lipid accumulation, are 
399 direct effects of rare sugars or a result of changes in blood glucose and insulin.  
400 The accumulation of lipid in non-adipose tissue is considered to be a factor in several non-
401 communicable diseases.  Fat infiltration in liver and muscle tissue is associated with insulin 
402 resistance(84), and in NAFLD lipid accumulates in hepatocytes causing liver damage(85).  NAFLD 
403 is closely associated with insulin resistance and obesity, and is one of the most common causes 
404 of chronic liver disease worldwide, with estimated global prevalence of 24%(86).  While rare 
405 sugars have been found to protect against lipid accumulation in the liver in DIO animals, the 
406 effect of rare sugars on lipid accumulation in muscle tissue does not appear to have been studied.  
407 Research in this area could provide useful insights into the potential therapeutic benefits of rare 
408 sugars.  
409 Alterations in incretin response and appetite regulation
410 The question of whether rare sugars can affect appetite in people has not been extensively 
411 researched, and most of the animal studies in this review found no significant differences in food 
412 intake with rare sugar administration.  However, some studies reported that PSI consumption 
413 results in decreased food intake(43; 51; 60; 66), and there are several mechanisms of action by which 
414 rare sugars could potentially affect appetite.    
415 Leptin plays an important role in long-term appetite regulation; it suppresses appetite and 
416 increases energy expenditure(39).  Six animal studies found significantly decreased leptin levels 
417 with PSI supplementation(41; 42; 60; 65; 66; 71).  This could be explained by the decrease in body fat 
418 observed in each study, as leptin is mainly secreted by adipose tissue.  The effect of rare sugars 
419 on leptin signalling in humans is not clear, with leptin levels found to increase(39) or remain the 
420 same(36) with daily PSI consumption despite significant reductions in body fat.  Although 
421 generally correlated with adiposity, leptin levels show substantial inter-individual variation and 
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422 are affected by inputs from the sympathetic nervous system, insulin levels and long-term dietary 
423 intake(87).  Further research is needed to investigate the potential effect of rare sugar intake on 
424 leptin signalling.  
425 Appetite is also regulated by gut hormones such as GLP-1 and GIP which, in addition to their 
426 insulinotropic effects, slow gastric emptying.  PSI has been shown to stimulate the release of 
427 GLP-1 in animal studies(51; 88), an effect which could induce satiety and reduce food intake.  TAG 
428 has been found to stimulate GLP-1 release(52) and slow gastric emptying(52; 89) in human trials 
429 but the effect of rare sugar intake as part of a mixed meal has not to our knowledge been 
430 investigated.  
431 Dietary monosaccharides are known to affect appetite-regulating peptides in the hypothalamus; 
432 elevated glucose or fructose consumption have been shown to reduce the expression of the 
433 appetite-suppressing signals peptide YY (PYY) and pro-opiomelanocortin (POMC) expression(90).  
434 To our knowledge, the effects of rare sugars on hypothalamic appetite peptides have not been 
435 studied. Further work is needed to investigate the effects of different rare sugars on appetite, 
436 incretin release, gastric emptying and fullness in real-life conditions.  
437 Effects on inflammatory markers and oxidative stress
438 Obesity, T2D and CVD all involve inflammation and increased oxidative stress(83).  A reduction 
439 in inflammatory cytokines and oxidative stress could therefore be a key mechanism by which 
440 rare sugars may slow the progression of these conditions.  Several animal studies have found 
441 reduced markers of inflammation or oxidative stress when dietary sucrose or fructose were 
442 replaced with PSI(71; 73; 82).  Although in all of these studies the control group consumed more 
443 sucrose than the experimental group, the caloric intake was matched between groups so the 
444 reduction in inflammatory cytokines is unlikely to be a result of caloric restriction.  In one study 
445 in which TAG (30% solution), fructose (30% solution) or plain drinking water were provided to 
446 mice over 24 weeks, significantly increased TNFα and IL-1β levels were reported with fructose 
447 intake(69).  There were also significant increases in these cytokines with TAG intake, but the 
448 increase was around half of that with fructose.  As fructose provides around 4kcal per gram and 
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449 TAG is estimated to provide 2kcal per gram(5), these differences in inflammatory cytokine levels 
450 could be explained by differences in caloric intake between groups(69).  Studies using OLETF rats, 
451 a model for T2D, have found that PSI-treated animals had reduced fibrosis and fatty 
452 degeneration of pancreatic islets compared to control OLETF rats.  This protective effect was 
453 attributed to the reduced release of pro-inflammatory cytokines in PSI-fed animals(59; 60).  
454 Similarly, the replacement of dietary sucrose with TAG has been found to reduce atherosclerosis 
455 in animals(70; 91), although once again the possible contribution of caloric restriction must be 
456 taken into account(92).   
457 Effects on the gut microbiome
458 The composition of the gut microbiota can be affected by dietary change, and it is becoming 
459 increasingly clear that changes in the gut microbiome are linked to a wide range of health-related 
460 factors such as inflammatory state and adiposity(82).  Probiotics and polyphenol-rich fruit 
461 extracts, which improve the diversity of the gut microbiome, have been shown to also reduce 
462 visceral adiposity and obesity(45).  The impact of rare sugars on the gut microbiome has only 
463 recently been studied, but the results from animal studies indicate that PSI intake can increase 
464 the proportion of species such as Lactobacillus, thought to be protective against fructose-induced 
465 NAFLD(45).  TAG, as it is poorly absorbed, can act as a prebiotic, and has been shown to work 
466 synergistically with probiotics in reducing the susceptibility of mice to chemically-induced 
467 colitis(47).  This potential for changes to the gut microbiome requires further exploration in human 
468 studies, but should also be considered as a potential mechanism when interpreting the results 
469 of existing studies.  
470 The potential use of rare sugars as functional foods
471 Functional foods are those containing ingredients which exert positive health effects, and 
472 therefore have health promoting properties besides their nutritional value(17).  The majority of 
473 the evidence suggesting health benefits from long-term rare sugar consumption comes from 
474 animal studies that, if replicated in humans, could provide significant health benefits.  However, 
475 because of the very high-energy diets and large rare sugar dosages used in many of these trials, 
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476 there is doubt about whether similar effects would be seen in humans.  For example, the 
477 dramatic reduction in lipid accumulation in the liver seen in studies of PSI(41-46; 49) or ALL(27) 
478 consumption suggests an application for rare sugars in preventing NAFLD.  Only one of these 
479 studies(46) provides daily food intake data, stating that the ob/ob mice in the experimental group 
480 consumed 3-4g PSI per kg body weight per day, with control groups consuming an isocaloric 
481 diet of normal CE2 pellet food.  This quantity would equate to an intake of at least 210g PSI per 
482 day for an average 70kg human- a quantity clearly unrealistic for PSI consumption in foods. 
483 In this review the effects of long-term consumption in humans have been reported in only three 
484 studies using TAG in the USA and India(37; 38; 40), two studies using PSI in Korea and Japan(28; 36) 
485 and one study in Japan using RSS(39).  Although these trials did report significant benefits from 
486 rare sugar consumption, it is important to note that they involved relatively large doses of rare 
487 sugars taken as daily dietary supplements.  If rare sugars are to be promoted for their health 
488 benefits, research studies must take into account that they are more likely to be consumed in 
489 smaller quantities as part of reformulated food products.  
490 The rare sugar TAG is currently used as a sweetener (branded ‘Tagatesse’) in products sold by 
491 Damhert Nutrition in Belgium, the Netherlands and Luxembourg(10).  A typical product, gluten-
492 free spiced biscuits, contains 0.6g TAG per 10g portion.  In contrast, participants in the 2015 
493 trial conducted by Ensor et al.(40) consumed 15g of TAG three times per day.  Products containing 
494 PSI are also available, primarily in the USA, where items such as soft drinks, protein bars and 
495 cookies are sweetened with PSI(11).  For example, Quest hero bars, marketed as low-
496 carbohydrate snacks, contain 11g PSI per 60g bar (along with erythritol and soluble fibre)(93).  
497 This quantity is more comparable to the amounts used in clinical trials, for example Han et al.(36)  
498 reported significant reductions in body weight and BFP when overweight participants consumed 
499 7g PSI twice daily for 12 weeks, compared to a control group consuming a sucralose placebo.  
500 The cost of rare sugar production has been reduced by advances in biotechnology.  The cost of 
501 PSI is now estimated at $7/kg, comparable with erythritol(94).  Recent advances in genetic 
502 engineering have produced yeasts that can generate TAG from whey waste from yogurt making, 
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503 greatly reducing its cost(7).  Rare sugars are therefore becoming attractive alternatives to other 
504 sweeteners in the reformulation of products.  
505 Another important consideration if rare sugars are to be used in the reformulation of foods is 
506 their sensory properties.  Rare sugars tend to be slightly less sweet than sucrose but have similar 
507 sweetness profiles, suggesting that the temporal sweetness profile and sweetness quality may 
508 be similar to sucrose but the intensity will be lower(14; 95).   When used in combination with 
509 sucrose, some rare sugars can provide desirable sensory characteristics whilst also reducing 
510 calories(14; 95).  
511 In considering the use of rare sugars within functional foods and in the reformulation of foods, 
512 it is also vital to consider the safety of long-term rare sugar intake.  Both PSI and TAG have 
513 been given GRAS status(8; 9).  In tolerance testing in healthy volunteers, the maximum single 
514 dose of PSI that resulted in no severe gastrointestinal symptoms was 0.4g per kg body weight(75) 
515 although Hayashi et al.(28) reported no evidence of toxicity with a single dose of PSI at 0.5-0.6g 
516 per kg body weight.  A large clinical trial investigating the safety and efficacy of TAG for treating 
517 patients with T2D reported no toxic effects on renal or hepatic function, although there were 
518 transient mild gastrointestinal symptoms(37).  One consideration in the assessment of the safety 
519 of sugars is their natural presence in a typical human diet.  PSI exists in small amounts in wheat 
520 and Itea plants as a free sugar, but more substantial amounts (up to 135mg/100g) are formed 
521 when fructose undergoes cooking processes, such as in Worcester sauce, brown sugar, maple 
522 syrup, ketchup, and cola(15).  TAG occurs naturally in Sterculia setigera gum and small quantities 
523 have been found in sterilized and powdered cow’s milk, a variety of cheeses, and other dairy 
524 products(96).  Nonetheless, it is vital to consider the effects of large-scale increases in the intake 
525 of these sugars in a population.  The rare disaccharide trehalose appears naturally in small 
526 amounts in mushrooms, honey and other foods and was considered GRAS.  However, when it 
527 begun to be widely used in the manufacture of baked goods and cereals, average intakes 
528 increased from less than 0.3g per day to over 30g per day.  This change in nutrient availability 
529 led to the evolution of strains of the pathogenic bacterium Clostridium difficile which were able 
530 to utilise trehalose as an energy source, and therefore outcompete other gut microbiota(97).    The 
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531 effects of increased intake of rare monosaccharides on the gut microbiome should be carefully 
532 considered before encouraging increased general intake of rare-sugar-containing products.  
533 The GRAS status, suitable sensory characteristics and reasonable costs of both PSI and TAG 
534 make them attractive options as novel sugar replacers in the reformulation of food products.  
535 However there is a need for further long-term human trials in different populations, using 
536 realistic dosages within real food matrices, with careful monitoring of adverse effects and impact 
537 on gut microbiome before any of the promising results from animal studies can be translated 
538 into health claims for rare sugars as functional foods.  
539 Implications for research 
540 This review has highlighted gaps in the research on the use of rare sugars.  Studies in this field 
541 have tended to focus on either postprandial glucose metabolism, long-term glycaemic control, 
542 or lipid metabolism.  As a result, there is a lack of research linking these different areas.  
543 Research to date has been predominantly conducted in animals, often using DIO animals 
544 consuming high-energy diets, for example several studies(41-45) involved PSI intake as 5% of a 
545 weight-promoting diet (replacing sucrose), with control diets typically containing 20% fat and 
546 37% sucrose by weight(41).  This is a widely-used method to model obesity in rodents(98), but 
547 may not accurately represent the complexities of energy metabolism in humans consuming an 
548 unhealthy diet.  The small number of human studies to date have been carried out in limited 
549 populations (PSI and RSS primarily in East Asian subjects, TAG mainly in subjects with T2D).  
550 The details of how rare sugars are absorbed, metabolised and excreted in humans are not yet 
551 known.  PSI and ALL are both found in human urine at levels higher than would be expected 
552 considering extremely low levels in the diet, highlighting gaps in our knowledge of their 
553 metabolism(99).  The mechanisms by which rare sugars exert their effects are not fully 
554 understood, therefore it is not possible to draw conclusions on their potential health benefits in 
555 different populations.  The majority of the human trials have involved rare sugar solutions as a 
556 supplement, and there is no evidence to date for health benefits of rare sugar consumption in 
557 reformulated products as part of a normal diet.  In order for rare sugars to be classed as 
558 functional foods, robust evidence would be required demonstrating measurable improvements 
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559 in health markers or outcomes from regular consumption of reformulated foods containing rare 
560 sugars.  
561 One of the key differences in research methodology highlighted by this review is the nature of 
562 the control conditions.  While many researchers took steps to reduce or eliminate the effect of 
563 differences in caloric intake between groups, some studies used rare sugars to replace other 
564 carbohydrates in the diet, and thus there was a difference in energy intake between groups.  In 
565 some cases this difference was substantial, for example in one study in mice where all of the 
566 sucrose in a Western diet (34% of the diet by weight) was replaced by TAG(91).  It is possible 
567 therefore that the reduced serum lipids, reduced atherosclerotic lesions and reduced adipose 
568 tissue weight observed in this study were partly a result of caloric restriction.  Reduced calorie 
569 intake can rapidly lead to decreased triglyceride levels in tissues including the liver, reduced 
570 visceral fat and increased insulin sensitivity in people with obesity(92), therefore it is vital that 
571 studies exploring similar effects with rare sugar intake ensure that experimental and control 
572 diets are isocaloric.  Overall food intake should also be monitored and reported.  Several animal 
573 studies in this review reported reduced food intake with PSI(43; 46; 51; 60; 62) or RSS(66; 74) 
574 supplementation, suggesting a possible effect on appetite.  In long-term studies in people, where 
575 there may be large differences in energy intake between different participants, small changes in 
576 appetite with rare sugar intake could result in differences in energy intake which may not be 
577 detected even with careful dietary monitoring.  Even in studies with isocaloric diets and 
578 monitored food intakes, the type and quantity of carbohydrates in experimental and control diets 
579 should be considered carefully.  Consumption of fructose and HFCS are known to have 
580 detrimental effects on lipid metabolism and insulin sensitivity(100), and have been linked to 
581 increased cardiovascular risk and diabetes prevalence(101).  It is important when examining the 
582 benefits of a rare sugar to consider whether rare sugar consumption is ‘better than nothing’ or 
583 only ‘better than other free sugars’.  
584 Short-term studies in both healthy volunteers and subjects with T2D have demonstrated a 
585 reduction in PEBG when a single dose of PSI or TAG is consumed alongside a carbohydrate 
586 load(28; 29; 31-34; 52; 57).  However, it is not clear whether this effect persists when rare sugars are 
Page 26 of 64
Cambridge University Press
British Journal of Nutrition
For Review Only
587 consumed regularly(36; 39).  Additionally, the importance of the timing of rare sugar consumption 
588 relative to the carbohydrate load, and the effects of rare sugar consumption on appetite, have 
589 not to our knowledge been investigated in humans.  These are important considerations if health 
590 claims are to be made for products containing rare sugars as replacements for free sugars.  
591 Many animal studies(36; 39; 41-46; 48; 49; 59; 62; 63; 66; 71-74), and two studies in humans(36; 39), have 
592 reported reductions in body fat with PSI or RSS intake.  This hypolipidemic effect appears to be 
593 mediated by changes in the expression or activity of enzymes involved in lipid metabolism (see 
594 Figure 3).  Importantly, the in vivo effects of PSI tend to oppose the effects of insulin.  It is 
595 possible that reduced circulating insulin is the primary factor leading to reduced lipogenesis and 
596 increased oxidation of fatty acids.  However, there were no significant changes in fasting insulin 
597 levels in the human studies(36; 39), or in the animal studies in which it was measured(62; 63; 70).  
598 While both PSI and TAG have been shown to stimulate GLP-1 release(51; 52; 88), it is only in mice 
599 that this has been linked to increased insulin release(51).  It is possible that rare sugars may 
600 potentiate insulin release in the short term, while improving insulin sensitivity and thus reducing 
601 basal insulin levels in the longer term.  Further large-scale, long-term trials in different human 
602 populations would help to clarify the effect of rare sugars on insulin secretion and shed light on 
603 the mechanisms for the hypolipidemic effects of rare sugars.  
604 Limitations of this review
605 The process of a scoping review, as distinct from a systematic review, has certain limitations.  
606 In order to rapidly map the existing literature, inclusion criteria were broad and study selection 
607 was not subject to the quality assurance typical in a systematic review.  The quality of individual 
608 studies has not been formally assessed, and some evidence has been extracted from abstracts 
609 of papers, so detailed methods cannot be examined.  
610 When attempting to collate and report data from a range of different studies there is necessarily 
611 a degree of over-simplification.  This review has largely reported on significant effects and their 
612 direction, but has not attempted to quantitatively compare effect sizes.  Studies are not always 
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613 directly comparable because of differences in animal models or subjects, rare sugar dosages and 
614 timescales.  
615 When considering the results of human trials, it is significant that most of the studies carried out 
616 to date have been in East Asian populations.  Differences in genetics and habitual diet could limit 
617 the extent to which these results can be generalised to other populations.  Additionally, most 
618 studies have involved the acute administration of rare sugars in drinks or syrups.  The effects of 
619 rare sugars as part of a typical human diet, and in different food matrices, are largely unknown.  
620 Summary
621 This scoping review has summarised the research into the observed health benefits of rare 
622 sugars.  The majority of research has focussed on PSI, but other rare sugars have been shown 
623 to have beneficial effects.  
624 Rare sugars have been shown to improve glycaemic control and reduce body fat in human clinical 
625 trials as well as in animal studies.  The effect of lowering postprandial glucose levels could lead 
626 to multiple health benefits, and rare sugars may also affect other pathways linked to obesity, 
627 T2D, NAFLD and CVD, for example by altering lipid metabolism, improving the gut microbiome 
628 or reducing inflammation.  Therefore the consumptio  of rare sugars, whether as sugar 
629 replacers, dietary supplements or in functional foods, could potentially provide health benefits.  
630 However, the number and scale of human studies is still limited, and the dosage, timing and 
631 frequency of consumption required to see beneficial effects in humans is not known.  There are 
632 questions to be answered about the long-term efficacy of rare sugars and their effects on health 
633 outcomes in different populations.  A clearer understanding of the absorption and metabolism of 
634 rare sugars in humans, their effects when consumed in realistic doses as part of reformulated 
635 foods, and their mechanisms of action, is vital when considering the potential benefits of rare 
636 sugars in the human diet.  
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Tables
Table 1: Summary of the reported health benefits of rare sugar consumption (including only studies reporting significant results)
Human studies Animal studiesObserved Effect of 
Rare Sugar
Subjects with T2D, 
hyperglycemia or obesity





















TAG Ensor 2014(38), 2015(40) PSI Baek 2010(58)
Do 2019(41)+
Han 2016(42)
Hossain 2011(43). 2012(59). 2015(60)
PSI Iida 2013(66)+





RSS Hayashi 2014(39)+ PSI
TAG































Improved plasma lipid 
profile
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TAG Williams 2015(91)*+






















PSI Pratchayasakul 2020(50)# PSI Chen 2017(48)*+#
Chen 2019(49)*+
Studies reporting inconclusive or non-significant results have not been included.  PEBG, postprandial elevation of blood glucose. 
 * indicates studies in which there was a possible calorie deficit in the experimental group.  + indicates studies in which the rare sugar replaced another carbohydrate in the 
experimental diet.  # indicates studies available as abstracts only.  
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Trial design RS dose CHO load Ratio 
RS:CHO 
Control Difference in AUC p value Conclusions
5g PSI in 
glucose 
solution
1:15  No addition 
to CHO load









age 37 ± 16










2:15 -23 ± 22 mmol/L*min
(10.3% reduction)
0.07
No significant effect on 
plasma glucose iAUC 









age 55.0 ± 11.4 














1:17 Aspartame -743.3 mg*min/dl 
overall for meal
(11.5% reduction)
<0.01 AUC for PSI meal was 
significantly less than 
control aspartame meal 
overall and in subgroup of 
subjects with borderline 
diabetes but not in subgroup 
of healthy participants.  






age 35.7 ± 2.0












(571kcal; 61% of 
energy as CHO, 
25% as fat, 14% 
as protein.  
(Estimated 93g 
CHO)
1:19 Aspartame NA NA PSI supplementation gave 
significantly lower change in 
plasma glucose at 90 min 
only, compared to 
aspartame control.  No 
significant difference in 




Subjects with T2D, 
controlled with diet 
or OHAs, not 
insulin (n=24)
age 66 ± 1.2














0.051 Significant linear dose 
response gradient for 
reduction in AUC for 
glucose.  
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10g PSI in 
glucose 
solution



















87.6g CHO for 
males, 513kcal, 






NA NA Postprandial glycaemic 
response significantly lower 
after PSI compared to D-
fructose control.  
















NA NA Dose-dependent reduction 
in postprandial blood 
glucose, with significant 










0, 1.8, 3.6 
or 12.5g 






NA NA NA NA Reduction in postprandial 
blood glucose and insulin 








0, 15, 25 
or 35g RSS
Total 50g CHO- 
sucrose with part 
replaced by RSS
3:7, 5:5 or 
7:3
sucrose NA Compared to 100% sucrose 
control, 5:5 and 7:3 ratios 
gave significant reduction in 
iAUC for glucose and insulin.  
3:7 ratio gave significant 
reduction in iAUC for insulin 








5g RSS Total 10g CHO- 




Significant reduction in iAUC 
for glucose and insulin with 
1:1 RSS:sucrose compared 
to sucrose alone.  
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1:1 sucrose NA Significant reduction in iAUC 
for glucose compared to 

















Significant reduction in iAUC 
for glucose compared to 
sucrose control.  





Age 35.8 ± 1.45




-3.3 mg/dL/h (1.32% 
reduction)
NS
Significant reduction in iAUC 




fasting glucose or 
newly-diagnosed 
T2D, n=33) 
Age 57.2 ± 1.71
















-15.4 mg/dL/h (4.0% 
reduction)
<0.05





Age 28.2 ± 4.0




















NS Significant increase in iAUC 
with glucose preload, but no 
significant differences 
between TAG and control.  
Difference in iAUC (incremental area under curve) for glucose is the difference between rare sugar treatment group vs control group in 120 minutes following ingestion of carbohydrate 
load.  P-values are for significance of difference as stated in the referenced article.  Ages are given in years, body mass index (BMI) is given in kg/m2. Shaded rows are articles not 
available in English.  RS, rare sugar; PSI, D-psicose; CHO, carbohydrate; T2D, type 2 diabetes; OHAs, oral hypoglycaemic agents; NA, not available; RSS, rare sugar syrup; TAG, 
D-tagatose; NS, not significant.
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Table 3: the effects of in vivo PSI administration on the enzymes involved in lipid 
metabolism.  
Enzyme Role Effect of PSI References
Hepatic 
lipase
Hydrolysis of triacylglyceride Increased activity 48
Hepatic 
CPT1
Catalyses the rate-limiting step in the beta-
oxidation of long chain fatty acids.  
Increased expression or 
activity
73, 71, 41
Hepatic ME Catalyses conversion of malate to pyruvate, 
replenishing TCA cycle intermediates.  Provides 




Provides a source of NADPH for lipogenesis.  Decreased activity 73, 71, 65, 
68
ACC Catalyses the committed step in fatty acid 
synthesis
Reduced expression 48
No significant difference in 
activity
41FAS Catalyses the synthesis of long-chain fatty 
acids.  
Decreased activity or 
expression




Catalyses the rate-limiting step in the beta-
oxidation of long chain fatty acids.  
Increased expression 71
HSL Hydrolysis of long-chain fatty acids- inhibited by 
insulin.  
Increased expression 48, 41
PAP Catalyses the conversion of phosphatidate to 
diacylglycerol, regulates TAG synthesis.  
Decreased activity 73, 68
LPL Hydrolyses triglycerides in lipoproteins Decreased expression 41
ACAT Catalyses key step in the mevalonate pathway, 
promotes cholesterol storage.  
Decreased activity 73
PCSK9 Binds to LDL receptor, reducing LDL-R recycling.  Lower serum level 61
HMGCR Catalyses the rate-limiting step in cholesterol 
synthesis.  
Increased activity 73
CPT: carnitine palmitoyltransferase, ME: malic enzyme, G6PDH: glucose 6-phosphate 
dehydrogenase, ACC: acetyl-CoA carboxylase, FAS: fatty acid synthase, HSL: hormone-sensitive 
lipase, PAP: phosphatidate phosphatase, LPL: Lipoprotein lipase, ACAT: Acetyl-coenzyme A 
acetyltransferase, PCSK9: Proprotein convertase subtilisin/kexin type 9  HMGCR:  3-hydroxy-3-
methyl-glutaryl-coenzyme A reductase, TAG: triacylglycerol.  
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Figures
Figure 1: Identification and selection of relevant research.  PSI: D-psicose, TAG: D-
tagatose, SOR: D-sorbose, RSS: rare sugar syrup, ALL: D-allose.  
Figure 2: Mapping diagram to show the health benefits of rare sugars and how they 
are interlinked.  Blue text indicates actions of rare sugars demonstrated in at least one study 
included in this review.  Letters in brackets indicate the rare sugars involved, with capital letters 
denoting human studies and lower-case letters denoting animal studies: A/a – allose, P/p – 
psicose, S/s – sorbose, T/t – tagatose.  
Figure 3: Outline of fatty acid metabolism in the liver (A) and adipose tissue (B), 
highlighting the effects of insulin and PSI.  Green (+) or (-) indicates increased or decreased 
expression or activity stimulated by insulin.  Red (+) or (-) indicates increased or decreased 
expression or activity as a result of PSI consumption.  TG: triacylglycerol, VLDL: very low density 
lipoprotein, ACS: acyl-CoA synthase, ACC: acetyl-CoA carboxylase, CPT-1: carnitine-palmitoyl 
transferase 1, ME: malic enzyme, GLUT2: glucose transporter 2, GLUT4: glucose transporter 4, 
LPL: lipoprotein lipase.  Diagrams adapted from Frayn, 2019(83), p131 & 133.
Supplementary Data (provided separately)
Table S1: Search terms and results of literature searching.
Table S2a: Summary of included in vivo animal studies.
Table S2b: Summary of included studies in human subjects.
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Table S1: Search Terms and Results of Literature Searching
Search Search terms Scopus Web of 
Science
PubMed
1 D-psicose OR psicose OR D-psi OR 
allulose OR D-allulose 
551 687 303
2 D-tagatose OR tagatose OR D-tag 650 688 335
3 D-sorbose or sorbose OR D-sor 529 499 282
4 D-allose OR allose 381 437 246
5 ‘rare sugar’ OR ‘novel sweetener’ OR 
‘new sweetener’ OR ketohexose OR 
aldohexose
77 536 404
6 ?Glyc?emi* OR ‘blood sugar’ OR 
insulin OR diabetes OR HbA1c
356,952 680,350 703,422
7 Lipid OR adipose OR fat OR ‘body 
composition’ OR obesity OR lipo* OR 
NAFLD OR NASH OR ‘fatty liver’ 
80,712 1,301,826 1,264,128
8 ‘Cardiovascular disease’ OR CVD OR 
‘heart disease’ OR stroke OR 
atherosclerosis
503,577 700,494 537,047
9 Antioxidant OR ‘oxidative stress’ OR 
redox OR ‘reactive oxygen species’ OR 
‘free radical’ OR thioredoxin OR 
glutathione
42,011 846,983 706,203
10 1 AND (6 OR 7 OR 8 OR 9) 69 333 87
11 2 AND (6 OR 7 OR 8 OR 9) 40 272 79
12 3 AND (6 OR 7 OR 8 OR 9) 12 110 70
13 4 AND (6 OR 7 OR 8 OR 9) 23 213 84
14 5 AND (6 OR 7 OR 8 OR 9) 20 147 117
Unique references identified in database 123 613 425
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Table S2a: Summary of included in vivo animal studies. 




Overview of methods Outcome measures Key results and conclusions
25 Oku et al., 
2014
Japan Wistar rats SOR 0.0495g single 
oral dose.   
Test solutions (0.45g sucrose, 
0.45g sucrose + 0.0495g SOR, 
0.45g sucrose + 0.0495g L-
SOR) given orally in solution, 
plasma glucose and insulin 
measured every 30 minutes 
for 3 hours.  
Plasma glucose and 
insulin. 
With SOR: elevation of plasma glucose was 
suppressed after 30 and 60 minutes.  Plasma 
insulin was also lower at 30 and 60 minutes 
in SOR group compared to sucrose-only 
group.  




SOR 3% of diet for 
28 days.  
2 groups (n=7) given control 
diet or 3% SOR (replacing 
cornstarch) diet ad libitum for 
28d.  BW monitored.  At 
sacrifice, non-fasting blood 
collected for biochemical 
analysis and organ weights 
measured.  
BW and composition, 






No significant differences observed in BW, 
food intake or adipose tissue weights.  
Cecum weight increased and cecal pH 
reduced in SOR group.  
Serum insulin reduced, but no significant 
change in serum glucose, in SOR group.  Uric 
acid and aspartate aminotransferase 
reduced in SOR group.  No other significant 
differences observed.  
27 Yamamoto et 
al., 2017
Japan STAM mice 
(C57BL/6J 
injected with 
STZ then fed 
high fat diet to 
induce NASH)
ALL 2% of high fat 
diet for 3 
weeks.  
2 groups (n=5-8) of STAM 
mice given high fat diet or 
high fat diet with 2% ALL.  
Control group of C57BL/6J 
mice given normal diet.  BW 
monitored.  At sacrifice, organ 
weights and serum 
biochemical parameters 
measured.  Liver sections 
examined microscopically.    






and glucose.   Liver 
injury (NAFLD activity 
score)
 STAM mice had reduced BW, increased liver 
weight, and 7-fold higher fasting serum 
glucose compared to control mice.  No 
significant differences were observed 
between ALL-fed STAM and control STAM 
groups.  Serum ALT and AST were increased 
in STAM mice compared to control, 
indicating liver injury.  ALT level was reduced 
in ALL-fed STAM group compared to control 
STAM group, but was still significantly higher 
than control group.   No significant 
differences in serum triglyceride were seen 
between any groups. 
Hepatic lipid accumulation was increased in 
STAM mice compared to control, but in 
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STAM mice given ALL this was completely 
suppressed.  Scores of hepatic pathology 
were reduced in ALL-fed STAM mice 
compared to the STAM group.   
41 Do et al., 2019 Korea Male C57BL/6J 
mice
PSI 5% of high fat 
diet for 8 
weeks.  
2 groups (n=8), given either a 
high fat diet with 5% PSI 
(replacing sucrose), or an 
isoenergetic amount of high 
fat diet.  BW monitored.  At 
sacrifice body composition 
and organ weights measured, 
plasma, hepatic and fecal 
lipids, plasma adipokines and 
cytokines and hepatic enzyme 
activities measured.  Liver 
histopathology examined.  
BW and composition, 
feed efficiency ratio, 
plasma adipokines 
and cytokines, 
plasma, hepatic and 





With PSI: lower weight gain and feed 
efficiency ratio.  Reduced adipose tissue.  
Reduced liver weight, increased kidney and 
muscle weight.  Reduced plasma glucose, 
resistin and leptin.  Reduced fecal fatty acids 
and triglycerides, reduced plasma 
triglycerides, reduced hepatic triglycerides, 
fatty acids and cholesterol.   Reduced 
activities of G6PDH, PAP, ACAT but no 
significant difference in FAS or enzymes 
involved in β-oxidation.  Smaller and fewer 
lipid droplets in liver, smaller adipocytes.  
42 Han et al., 
2016
Korea Male C57BL/6J 
mice
PSI 5% of high fat 
diet for 16 
weeks.  
6 groups (n=10), given normal 
diet (control), high fat diet 
(control) or high fat diet with 
5% PSI, erythritol, glucose or 
fructose (replacing sucrose).   
BW monitored.  At sacrifice 
body composition measured, 
plasma, hepatic and fecal 
lipids, plasma adipokines and 
hepatic enzyme activities 
measured.  
BW and composition, 
plasma adipokines, 
plasma, hepatic and 
fecal lipids, hepatic 
enzyme activities.  
With PSI: lower weight gain and feed 
efficiency ratio.  Reduced plasma leptin and 
resistin. Reduced liver weight, increased 
kidney and muscle weight.  Reduced white 
adipose tissue.  Values in PSI group close to 
normal diet control.  Reduced plasma 
triglycerides, total cholesterol and LDL-
cholesterol.  Reduced hepatic free fatty 
acids, triglycerides and cholesterol.  Reduced 
fatty acid synthase activity and increased β-
oxidation activity in adipose tissue.  
43 Hossain et al., 
2011
Japan OLETF rats PSI 5% solution in 
drinking water 
for 14 weeks.  
OLETF rats (n=15 per group) 
given plain water, 5% PSI 
solution or 5% glucose 
solution. Blood glucose 
measured periodically, OGTT 
at 14 weeks, liver and 
pancreas histology at 
sacrifice, immunostaining of 
BW and composition, 
AUC for glucose and 




With PSI: lower weight gain and food intake.  
Reduced abdominal fat.  Reduced AUC for 
glucose and insulin.  Although periodical 
blood glucose increased gradually in OLETF 
control and glucose-fed groups, it was static 
in LETO control and PSI-fed OLETF rats from 
3 weeks.  
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liver tissue for glucokinase 
(GK).  
GK translocation to cytoplasm impaired in 
OLETF control rats, but no significant 
difference between LETO control, PSI-fed 
and glucose-fed groups.   
44 Han et al., 
2020
Korea Male C57BL/6J 
mice
PSI 5% of high fat 
diet for 16 
weeks.  
4 groups (n=10) given normal 
diet, high fat diet, high fat 
diet + 5% PSI or 5% erythritol 
(substituted for sucrose).  BW 
monitored and energy 
expenditure measured.  At 
sacrifice body composition 
measured, plasma lipids and 
adipokines measured, gut 
microbiota and short chain 
fatty acids measured.  
BW and composition, 
plasma lipid profile, 
plasma adipokines, 
energy expenditure, 
gut microbiota and 
short chain fatty 
acids.  
Liver histopathology.  
With PSI: lower BW compared to high fat 
diet and erythritol groups.  Adipose tissue 
weight dramatically reduced compared to 
high fat diet group.  Total cholesterol, HDL 
and non-HDL cholesterol decreased 
compared to high fat diet.  Fatty acid 
synthase activity reduced and β-oxidation 
activity increased in white adipose tissue.  
Significant increase in energy expenditure.  
PSI and normal diet groups showed higher 
diversity in gut microbiota than high fat diet 
group.  
Reduced accumulation of lipid droplets in 
hepatic tissue with PSI compared to high fat 
diet group.  Fibrotic tissue absent in normal 
diet and PSI groups, present in high fat diet 
and erythritol groups.  
45 Han et al., 
2020
Korea Male C57BL/6J 
mice
PSI 5% of high fat 
diet for 16 
weeks.  
3 groups (n=9) given normal 
diet, high fat diet or high fat 
diet + 5% PSI (substituted for 
sucrose).  BW monitored.  At 
sacrifice body composition 
and plasma inflammatory 
markers measured.  
Expression of genes in liver 
and white adipose tissue 
measured.  




of gene expression in 
liver and white 
adipose tissue, gut 
microbiota.  
With PSI: reduced BW and adipose tissue 
weight, no significant difference in food 
intake.  Reduced hepatic lipid content.  PSI 
supplementation reversed the differences in 
organ weights seen with high fat diet.  
Groups of up/downregulated genes 
identified as associated with obesity-related 
inflammation, reduced to near normal-diet 
levels with PSI.  PSI diet increased beneficial 
bacteria Lactobacillus and Coprococcus.  
46 Itoh et al., 
2015
Japan C57BL/6J mice 
(ob/ob  and 
wild-type)
PSI 2.5% or 5% of 
diet for 15 
weeks.  
3 groups (n=14) of ob/ob mice 
given 0, 2.5 or 5% PSI, control 
group (wild-type) given 
normal diet. BW monitored, 
BW and composition, 
hepatic steatosis.
BW gain lower in 5% PSI group than in ob/ob 
control.  Liver weight, visceral fat and fat 
mass lower in PSI groups than ob/ob control, 
with no difference in fat-free mass.  Livers of 
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hepatic steatosis and fat 
deposition measured by MRI.  
Body composition and 
histological examination at 
sacrifice.   
ob/ob mice showed signs of hepatic 
steatosis not present in wild-type mice- this 
was inhibited in 5% PSI group.  
47 Son et al., 
2019
Korea BALB/c mice TAG 25mg every 
other day for 





GG (LGG), by 
oral gavage.  
4 treatment groups (n≥3) 
given PBS, TAG, LGG or 
LGG+TAG for 3 weeks.  In 3rd 
week dextran sulphate 
sodium (DSS) added to 
drinking water to induce 
colitis.  
BW, food intake and 
colitis disease activity 







of colon undertaken, 
serum IL-6, IL-10 and 
TNFα determined.  
DSS induced colitis symptoms (reduced BW, 
diarrhoea, bloody stools), as well as reduced 
colon length, irregular crypt structure, 
inflammatory cell infiltration, increased 
serum IL-6, IL-10 and TNFα.  Group given 
LGG+TAG were less susceptible to colitis 
than LGG group or TAG group- had higher 
BW, higher food intake and reduced 
diarrhoea scores.  BW was higher in TAG, 
LGG and LGG+TAG groups than in DSS group.  
In all 3 ‘treatment’ groups, the reduced 
colon length and acute inflammation seen 
with DSS treatment were attenuated, with a 
synergistic effect with LGG+TAG.  All 3 
treatments reduced serum IL-6 and IL-10, 
but only LGG+TAG reduced serum TNFα.  
The effects of DSS-induced colitis on the 
intestinal bacterial communities were 
reduced in the LGG+TAG group.  




China Wistar rats PSI 5% of diet for 
4 weeks.
5 groups given 5% glucose, 
fructose, cellulose or PSI.  At 
sacrifice, blood lipid profile, 
tissue morphology and genes 
involved in lipid metabolism 
measured.    
BW, body fat, plasma 
lipid profile, 
expression of genes 
related to lipid 
metabolism.  
With PSI: lower weight gain, reduced 
epididymal fat, smaller adipocyte size, 
improved blood lipid profile and antioxidant 
level.   Increased expression of succinate 
dehydrogenase and hepatic lipase.   
49 Chen et al., 
2019)
China Male Wistar 
rats
PSI 5% of diet for 
4 weeks.  
5 groups (n=6) given AIN-76A 
diet or the same diet with 
CHO partially replaced with 
5% glucose, fructose, 
cellulose or PSI.  BW 
measured every two days.  At 
BW, body fat, plasma 
lipid profile, hepatic 
gene expression.  
With PSI: lower weight gain, reduced 
abdominal and epididymal fat, reduced 
plasma triglyceride, free fatty acids and LDL 
cholesterol compared to control.  Increased 
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sacrifice body fat, plasma 
lipids and hepatic gene 
expression measured.  






Thailand Rats PSI 1.9g per kg 
BW per day 
for 12 weeks
Rats (n=56) fed control diet or 
HFD for 12 weeks. HFD-fed 
rats then given PSI or 
metformin for 12 weeks.  
Cognition and brain 










cognitive decline.  
All stated cognition and brain parameters 
were observed in HFD rats.  Both PSI and 
metformin attenuated brain oxidative stress, 
mitochondrial reactive oxygen species 
production and hippocampal apoptosis and 
improved learning.  Metformin gave greater 
improvement than PSI in brain mitochondrial 
dysfunction and microglial hyper-activation, 
and improved both learning and memory.  
51 Iwasaki et al., 
2018




PSI 0.3, 1 or 3g 
per kg BW 
single dose.  
1g per kg BW 
per day for 10 
days.  
PSI given orally or by 
intraperitoneal injection. 
Food intake monitored.  
Blood glucose, insulin and 
GLP-1 measured before and 
after intraperitoneal glucose 
injection.  
PSI given orally at onset of 
light or dark period.  Food 
intake monitored, blood 
glucose and insulin measured 
before and after 
intraperitoneal glucose 
injection.  
Food intake, GLP-1 
secretion, response 
in glucose tolerance 
test.  
Oral PSI administration decreased food 
intake for 6 hours without aversion.  
Cumulative intake normalised after 24 
hours.  This effect was not seen in GLP1r-
knockout mice, nor when PSI given by 
injection.  Oral PSI administration 60 
minutes before glucose injection attenuated 
increases in blood glucose at 15, 30 and 60 
minutes without affecting basal blood 
glucose, and increased insulin release at 15 
minutes.  
Daily oral PSI administration at onset of light 
period reduced food intake during light 
period, reduced fasting blood glucose and 
attenuated hyperinsulinaemia in diet-
induced obese mice.  Blood glucose and 
insulin after glucose injection were also 
reduced.  Effects were not significant in GLP-
1r knockout mice, nor if PSI was given at 
onset of dark period.  
54 Yagi and 
Matsuo, 2009
Japan Wistar rats PSI 3% of diet for 
12-18 months.   
2 groups (n=18) given diet 
with 3% sucrose or D-psi ad 
libitum. BW, food intake and 
BW, organ weight 
and morphology, 
haematological and 
BW not significantly different between 
groups at 12 months but reduced in PSI 
group at 18 months.  With PSI: liver and 
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symptoms of toxicity 
monitored.  At sacrifice, organ 
weight and morphology 
examined, blood biochemical 
parameters measured.   
biochemical 
measurements.  
kidney weights increased at 12 and 18 
months, brain, lung and pancreas and cecum 
weights increased at 18 months, intra-
abdominal adipose tissue weight reduced at 
18 months.  No significant differences in 
chemical values.  Fatty degeneration & 
hepatocellular fibrosis observed in PSI but 
not sucrose group, slight increase in 
pathological lesions in liver at 18 months.  
Overall effects not suggestive of overt PSI 
toxicity.  
58 Baek et al., 
2010
Korea Male C57BL/6J 
db/db mice
PSI 200mg per kg 
BW for 4 
weeks.  
4 groups of db/db mice (n=10) 
given water, PSI, D-glucose or 
fructose orally.  Wild-type 
control group given water.  
BW, plasma glucose and 
insulin, plasma, liver and fecal 
lipids measured.  OGTT at 28 
days.  
BW, plasma glucose 
and insulin, AUC for 
glucose in OGTT, lipid 
profiles.  
With PSI: lower weight gain, lower plasma 
glucose compared to all groups.  No 
significant difference in AUC for glucose in 
OGTT compared to control.  Lower liver 
triglyceride and total cholesterol, no 
significant difference in plasma or fecal 
lipids.  
59 Hossain et al., 
2012
Japan OLETF rats PSI 5% solution in 
drinking water 
for 13 weeks.  
OLETF rats (n=15 per group) 
given plain water, 5% PSI 
solution or 5% glucose 
solution.  BW and 
composition monitored.  
Periodical fasting blood 
glucose and OGTT 
measurements.  At sacrifice 
serum adipokines measured 
and adipose tissue and 
pancreas morphology 
examined.  
BW and composition, 
AUC for glucose in 







With PSI: lower weight gain with no change 
in food intake.  Reduced total fat and % fat 
mass.  Reduced fasting blood glucose and 
AUC for glucose in OGTT.  Reduced insulin 
resistance.  OLETF control group had 
evidence of fibrosis and fatty degeneration 
in islets, absent in PSI-fed group.  
60 Hossain et al., 
2015
Japan OLETF rats PSI 5% solution in 
drinking water 
for 60 weeks.  
OLETF rats (n=10 per group) 
given 5% PSI solution or 
normal drinking water.  LETO 
control rats fed normal diet.  
Fasting and postprandial 
AUC for glucose in 
OGTT, degree of 
insulin resistance 
(HOMA), plasma 
lipids, cytokines and 
With PSI: reduced postprandial blood 
glucose from 35 weeks.  Reduced plasma 
insulin and reduced insulin resistance (PSI-
fed OLETF similar to LETO rats).  Reduced 
inflammatory cytokines.  Fibrotic, 
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blood glucose measured 
periodically.  OGTT, plasma 
lipids, adipokines and 
cytokines measured.  At 








disorganised islets observed in OLETF control 
group, much less prominent and severe in 
PSI-fed group.  
61 Kanasaki et al., 
2019
Japan Golden Syrian 
hamsters
PSI 3% of normal 
diet or high 
fat diet for 8 
weeks.  
2 groups (n=8) given normal 
diet with or without 3% PSI.  2 
groups (n=8) given high fat 
diet for 4 weeks then high fat 
diet with or without 3% PSI 
for 4 weeks.  BW monitored, 
serum glucose, insulin, lipids 
and PCSK9 measured.  
BW, serum glucose, 
insulin, lipids and 
PCSK9.  
Normal diet hamsters: no significant 
differences in BW, serum glucose or insulin.  
Reduced cholesterol in VLDL and medium 
LDL, increased cholesterol in very small LDL 
and HDL, reduced LDL/HDL ratio.  
High fat diet hamsters: Reduced cholesterol 
in LDL, particularly medium and small LDL. 
Reduced LDL/HDL ratio.  
Both groups had reduced serum PCSK9 with 
PSI compared to control.  PSI seems to 
improve cholesterol metabolism, possibly by 
reducing serum PCSK9.  
62 Ochiai et al., 
2013
Japan Wistar rats PSI 5% of diet for 
8 weeks.  
Rats fed high sucrose diet for 
7 weeks, then 4 groups (n=8) 
given high starch diet with PSI 
(NP) or cellulose (NC) or high 
sucrose diet with PSI (SP) or 
cellulose (SC).  BW monitored, 
serum lipids, insulin and 
leptin measured, liver 
glycogen and lipids measured 
at sacrifice.  
BW, serum lipids, 
insulin and leptin, 
hepatic CHO and 
lipid content.  
With PSI, reduced BW gain and adipose 
tissue weight.  For rats on high sucrose diet, 
PSI reduced serum HDL and LDL cholesterol 
and increased non-esterified fatty acids.  No 
significant differences in serum glucose, 
insulin or leptin.  Hepatic triglyceride and 
cholesterol higher with PSI in high-starch 
diet groups, but no significant differences in 
hepatic glycogen.  
63 Ochiai et al., 
2017





30% of diet 
for 8 weeks.  
4 groups (n=8) given high 
sucrose control, HFCS, RSS or 
MGS in ad libitum diet.  
Sucrose (approx. 30% of diet 
w/w) replaced with HFCS, RSS 
(PSI 1.5%, SOR 2.9%, TAG/ALL 




With RSS, reduced adipose tissue weight and 
body fat percentage compared with sucrose 
group.  Reduced food efficiency with RSS and 
MGS.  Increased liver and kidney weights 
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1.1% of diet) or MGS (PSI 
3.3% of diet) for 8 weeks.  
Food intake and BW 
monitored.  At sacrifice, organ 
weights recorded and 
biochemical analysis of serum 
conducted.  
cholesterol.  Liver 
lipid profile.    
with both RSS and MGS compared to 
sucrose.  
No significant differences in blood 
biochemical parameters.  
64 Pongkan et al., 
2020
Thailand Male Wistar 
rats
PSI 1.9g per kg 
BW per day 
(3% solution 
in drinking 
water) for 12 
weeks
4 groups (n=6). 3 groups fed 
HFD for 12 weeks (control 
group fed ND).  HFD groups 
then given PSI, metformin 
(300mg/kgBW/day) or sterile 
drinking water for 12 weeks.  
Cardiac function measured at 
12 and 24 weeks.  Plasma 
glucose, insulin and lipids 
measured and insulin 
resistance estimated, OGTT 
carried out, markers of 
cardiac dysfunction measured 
at 24 weeks.  
Electrocardiograph 
for cardiac function, 













No significant difference in food intake per 
body weight, but HFD animals had increased 
body weight and visceral fat.  No significant 
difference in body weight or visceral fat with 
PSI compared to HFD group.  PSI and 
metformin both attenuated insulin 
resistance, metformin improved lipid profile 
but no significant difference in lipids with 
PSI.  Both PSI and metformin improved 
cardiac function, reduced cardiac oxidative 
stress, reduced evidence of cardiac 
mitochondrial dysfunction and reduced 
levels of cardiac apoptotic proteins 
compared to HFD group.  




PSI 3% of diet for 
4 weeks.  
2 groups (n=24) given control 
diet or 3% PSI diet for 4weeks 
then 5-6 animals sacrificed 
every 6h over 24h without 
fasting.  2 groups (n=8) fed as 
above and energy 
expenditure measured over 
24hrs.  
Serum glucose, 
insulin, lipids and 
leptin, hepatic 
enzyme activity, 
gene expression in 
liver, small intestine, 
muscle and adipose 
tissue.  Total energy 
expenditure, fat 
oxidation and CHO 
oxidation.  
With PSI: reduced BW and food intake.  
Reduced serum insulin, leptin and total 
cholesterol at some timepoints, no 
significant difference in serum glucose.  
With PSI: decrease of G6PDH and ME (sig at 
9am).  Expr of PPARa sig higher in liver, Exp 
of MTP sig lower.    .  Total EE per kg BW sig 
higher during late light period Fat ox sig 
enhanced and carb ox sig reduced during 
dark period.  
66 Iida et al., 
2013
Japan Male Wistar 
rats
RSS 30% of diet 
(replacing 
3 groups (n=10), given diets 
containing 60% starch, 30% 
starch:30% HFCS or 30% 
BW and composition, 
plasma glucose, 
With RSS: Lower weight gain, reduced intra-
abdominal fat (dose-dependent effect).  
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50% of starch) 
for 8 weeks.  
starch:30% RSS.  BW 
monitored.  At sacrifice, body 
composition measured, 
fasting blood taken and 
plasma glucose, insulin, lipids 
and adipokines measured.  
insulin, lipids and 
adipokines.  
Fasting blood glucose reduced in HCFS and 
RSS groups compared to starch group.  
Plasma insulin reduced in RSS group 
compared to HCFS and starch.  No 
differences in plasma total cholesterol or 
triglycerides.  Leptin in RSS group lower than 
starch, in HCFS group higher than starch.  
67 Iga et al., 2010 Japan Wistar rats ALL Acute 
administration 
study: 15-25g 
per kg BW in 
single dose.    
Subchronic 
feeding study:    
0-3% in food 
for 6 months. 
Acute administration study: 
rats (n=4 per group) given 
single dose after 12h fast, 
fasted for 12h then observed 
for 48h. 
Subchronic feeding study: rats 
(n=10 per group) given ALL in 
food.  BW and food intake 
monitored. At sacrifice, 
haematological parameters 
and tissue weights measured.  
Acute administration 
study: number of 
deaths, LD50.      
Subchronic feeding 
study: BW, food 
intake, haematology, 
organ and tissue 
weights.  
Acute administration study: LD50=20.5g per 
kg BW.  
Subchronic feeding study: BW and feed 
efficiency ratio reduced in 3% ALL group 
compared to control.  Lungs, soleus and 
gastrocnemius muscle weights reduced in 
3% ALL group.  No significant differences in 
haematological parameters.  ALL concluded 
to be non-toxic in rats.  







3% of diet for 
4 weeks.  
5 groups (n=6) given AIN-93G 
diet with or without 3% rare 
sugar or fructose replacing 
cornstarch.  Sacrificed 
without fasting.  Serum and 
fecal lipids, hepatic enzyme 
activity and gene expression 
in liver and small intestine 
measured.  
Serum lipids, faecal 
lipids, hepatic 
enzyme activity, 
gene expression in 
liver and small 
intestine.  
No significant differences in BW, feed 
efficiency ratio or liver weight.  TAG-fed 
group had increased serum free fatty acids 
compared to fructose-fed group.  Faecal 
excretion of fatty acids was decreased by PSI 
but increased by SOR.  
Activity of fatty acid synthase was decreased 
by PSI but increased by TAG.  G6PDH and 
PAP expression was decreased in PSI-fed 
group compared to control.  Rare sugars 
affect lipid metabolism differently in rats.  
69 Collotta et al. 
2018
Italy C57BL/6J mice TAG 30% of solid 
diet or 30% 
syrup drink for 
24 weeks.  
5 groups (n=6) given a 30% 
TAG or fructose solid diet, a 
control diet with 30% TAG or 
fructose syrup or a control 
diet with water.  BW and 
BW, fasting glucose, 
HbA1c.  Plasma 
lipids, leptin, 
inflammatory 
markers and MDA 
Fructose-fed groups had higher weight gain, 
increased plasma fasting glucose and 
%HbA1c, increased leptin, serum triglyceride 
and LDL and decreased HDL, and a 3-fold 
increase in MDA.    No significant differences 
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glycaemia monitored.  Plasma 
lipids, adipokines, cytokines 
and markers of myocardial 
oxidative stress measured.  
(marker of 
myocardial oxidative 
stress) measured.  
were seen with TAG compared to control.  
Both fructose and TAG caused increased 
TNF-α and IL-1β, but the increase with TAG 
was half that of fructose.    




TAG 30% of diet 
for 16 weeks.  
2 groups (n=12, equal m/f) 
given TAG or sucrose diet for 
16weeks.  Control (n=10) 
given standard murine diet.  
TAG/sucrose introduced 
gradually over 3 weeks before 
16 week feeding period.  BW 
and food intake measured.  At 
sacrifice, organ weights 
measured, blood 
biochemistry analysed.  Aorta 
and adipose tissue 
morphology examined.     











High sucrose diet group had increased BW, 
energy intake, adipose tissue mass and 
adipocyte size, TAG-fed group similar to 
control.  Total cholesterol, VLDL and LDL 
increased with both sucrose and TAG 
compared to control, levels in the sucrose 
group higher than the TAG group.     
Atherosclerotic lesion area increased with 
sucrose compared to TAG and control, and in 
females in the TAG group compared to 
control.  Macrophage positive 
immunostaining seen in adipose tissue and 
aortic root of sucrose but not control or TAG 
groups.  TAG as a CHO source leads to 
increased total cholesterol and 
atherosclerosis, but significantly less than 
sucrose.  
71 Choi et al., 
2018
Korea Male C57BL/6J 
mice
PSI 3% of diet (PSI 
substituted 
for sucrose in 




12 weeks.  
7 groups (n=10), given high 
fat diet and two different 
probiotics with or without PSI.  
Control group given normal 
diet.  At sacrifice, after 16h 
fast, BW and composition, 
plasma lipids, adipokines and 
cytokines, hepatic lipids, 
enzyme activity and gene 
expression measured.  
BW and composition, 




enzyme activities & 
expression.  
With PSI: lower weight gain, reduced white 
adipose tissue.  PSI and probiotics worked 
synergistically.  Reduced plasma leptin, 
resistin and IL-1β in all groups fed PSI.  
Reduced activities of enzymes involved with 
fatty acid synthesis; increased activity of 
enzymes involved in β-oxidation in all groups 
fed PSI.         




PSI 2.5 or 5% of 
diet for 52 
days.  
Rats (n=10 per group) fed 
high fat diet for 4weeks to 
induce obesity, then either 
switched to normal diet or 
BW and composition, 
feed efficiency ratio, 
plasma lipids, organ 
With PSI: lower weight gain (dose-
dependent), food efficiency ratio and fat 
accumulation (greater effect in animals fed 
normal diet).  Increased serum total 
Page 53 of 64
Cambridge University Press
British Journal of Nutrition
For Review Only
kept on high fat diet with 5% 
sucrose, 5% eryrthritol or 
2.5/5% PSI for 52 days.  BW 
monitored, at sacrifice plasma 
lipids, body composition and 
organ weights measured.  
weights and 
histopathology.  
cholesterol, LDL-cholesterol and HDL-
cholesterol and liver weight in PSI-ND group 
compared to ND group.  No apparent 
differences in liver histopathology.  




PSI 5% of diet 
(replacing 
sucrose) for 
12 weeks.  
2 groups (n=15) given AIN-
93G diet or same diet with 
half of sucrose replaced with 
PSI (equivalent to 5% of diet). 
BW monitored, at sacrifice 
body composition, plasma 
lipids measured, adipose 
tissue morphology and gene 
expression examined.  
BW and composition, 
plasma lipids, 
adipose tissue 
histology and gene 
expression.  
With PSI: reduced final BW, white adipose 
tissue weight and adipocyte size.  Lower 
plasma total cholesterol, LDL cholesterol and 
LDL/HDL ratio.  No significant differences in 
triglycerides, free fatty acids or HDL 
cholesterol.  Reduced expression of markers 
of inflammation (TNFα, IL-6, MCP-1) and 
adipogenesis (PPARs, SREBP-1c, LPL, FAS), 
increased expression of markers of lipolysis 
(HSL) and beta oxidation (CPT-1).  
74 Shintani et al., 
2017








for 10 weeks.  
3 groups (n=10), given water, 
HFCS or RSS.  BW monitored.  
OGTT (2g per kg BW glucose) 
and insulin tolerance test 
carried out at 8 weeks.  At 10 
weeks, 4 rats per group 
sacrificed before and 30 min 
after a glucose load and livers 
examined for glucokinase 
translocation.  At sacrifice, 
tissue weights measured and 
liver analysed for glycogen 
content.    
BW and composition, 
AUC for glucose and 
insulin in OGTT, 
hepatic glucokinase 
distribution before 
and after glucose 
load, liver glycogen 
content.    
With RSS: reduced weight gain, decreased 
total abdominal fat compared to control.  
(HFCS had no effect on BW but increased 
abdominal fat).  
RSS decreased AUC for glucose and insulin in 
OGTT compared to control (AUC for glucose 
was increased by HFCS).  Insulin sensitivity 
increased by RSS (decreased by HFCS).      
Hepatic glycogen before glucose load was 3-
fold higher with RSS than control or HFCS.  
Glycogen in HFCS group was reduced after 
glucose load compared to control and RSS.  
GK translocation to cytoplasm was increased 
with RSS compared to HFCS or control, both 
before and after glucose load.  
76 Huang et al., 
2018
China Wistar rats PSI unknown 5 groups (n=?), given normal 
diet or supplemented with 
BW, plasma lipids, 
liver histology, 
With PSI: reduced BW, serum triglycerides, 
free fatty acids and LDL-cholesterol.  
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Increased expression of PPARα, reduced 
expression of fatty acid synthase.  




TAG 0, 0.6, 2 or 6g 
per kg BW, 





5 groups (n=8) given oral 
gavage containing 2g/kg 14C-
labelled fructose and varying 
doses of TAG.  Blood samples 
from femoral vein catheter at 
regular intervals for 60 mins.  
Blood glucose, 
plasma scintillation 
count to determine 
14C fructose.  
2 and 6g/kg TAG reduced AUC of fructose 
absorption by 26 and 30% respectively.  
No difference in blood glucose with 0.6 or 
2g/kg TAG, but 6g/kg TAG caused increased 
blood glucose from 30 mins (this attributed 
to stress caused by malabsorption effects 
from large doses of fructose and TAG)
88 Hayakawa et 
al., 2018
Japan Male C57BL/6J 
mice
PSI 0.5 – 2g per kg 
BW single oral 
dose.  
PSI, resistant maltodextrin, 
dextrin, fructose or water 
administered orally, with or 
without inhibitors of 
glucose/fructose transport.  
Plasma GLP-1, portal GLP-1 
and GIP measured.  Luminal 
contents measured at 60 and 
150min after administration.  
Plasma and portal 
GLP-1 and GIP, rate 
of PSI absorption, 




Oral PSI administration increased plasma 
GLP-1 in dose-dependent manner, and 
stimulated GLP-1 but not GIP in the portal 
vein.  Intraperitoneal injection of PSI did not 
stimulate GLP-1.  PSI absorption was slower 
than glucose (25% PSI remaining in stomach 
after 60 mins compared to 2.6% with 
glucose).  Inhibitors of SGLT1 and sweet 
receptor did not lower PSI-induced GLP-1 
secretion.  
91 Williams et al., 
2015
USA ApoE knockout 
mice




sucrose) for 8 
weeks.  
5 groups (n=8), given 
standard diet, Western diet 
(high fat & sucrose), Western 
diet with TAG, Western diet 
with BSN723 or Western diet 
with TAG and BSN723.  BW 
monitored.  At sacrifice body 
composition and evidence of 
atherosclerotic plaques 
measured.  
BW and composition, 
serum lipids, extent 
of atherosclerosis.  
TAG groups on Western diet showed lower 
BW gain than control Western diet group.  
Addition of TAG prevented the increase in 
adipose tissue caused by Western diet.  
Surface area of atherosclerotic lesions was 
greater in Western diet compared to 
standard diet; this was inhibited in TAG 
groups.  The increase in serum cholesterol as 
a result of Western diet was significantly less 
in the groups receiving TAG.  
Reported differences are statistically significant unless stated otherwise.  BW: body weight, PSI: D-psicose, TAG: D-tagatose, SOR: D-sorbose, ALL: D-allose, 
RSS: rare sugar syrup, HFCS: high fructose corn syrup, CHO: carbohydrate, AUC: area under curve, OGTT: oral glucose tolerance test, LDL: low density 
lipoprotein, HDL: high density lipoprotein, HFD: high fat diet, TNF-α: tumour necrosis factor α,  NAFLD: non-alcoholic fatty liver disease, NASH: non-alcoholic 
steatohepatitis, ND: normal diet, IL: interleukin, OLETF: Otsuka Long-Evans Tokushima Fatty, LETO: Long-Evans Tokushima Otsuka.  
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Table S2b: Summary of included studies in human subjects












Key results and conclusions






















study: 5g PSI 
given with meal, 
blood taken at 
30min intervals 






Meal-loading study: Plasma glucose was 
significantly lower at 30 and 60 min with all 
subjects after PSI meal compared to control meal.  
AUC for glucose (mg/ml/dl) for test meal 578.8+/-
2509.9, for control meal 6482.1+/-2953.8 (p<0.01 
for difference) 
Plasma glucose and AUC glucose significantly 
reduced with PSI, overall and in subjects with 
borderline diabetes but not in subgroup of healthy 
subjects.  
Safety 
study: 5g, 3x 
daily for 12 
weeks
Long-term safety 
study: 5g with 
meals for 12 
weeks. Fasting 
urine & blood 
taken at 2, 4, 8 




adverse effects.  
Long-term safety study: No significant differences 
observed in nutritional intake.  No persistent or 
serious adverse effects.   
29 Noronha 
et al., 2018
Canada Subjects (n=24) 
12m, 12f with 
T2D (controlled 

















75g OGTTs with 0, 
5 or 10g fructose 
or PSI added (6 
visits 1 week 
apart).  Blood 
taken every 30 
minutes for 120 
minutes, plasma 
glucose and 
insulin measured.  









With 10g PSI, significantly reduced iAUC for glucose 
(mol*min/l): 
5g PSI -48.1 (SE24.7, p=0.051)
10g PSI -601.1 (SE24.7, p=0.015) 
Significant linear dose response gradient for 
reduction.  Significantly reduced absolute mean 
plasma glucose with 5g.  
Equivalence test shows results within 20% 
equivalence boundaries, and reductions in 
glycaemic response were modest compared to oral 
antihyperglycaemic agents e.g. acarbose.  
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PSI 6g, single 
dose before 
meal
6g PSI or fructose 
given with normal 
lunch.  Blood 
taken regularly 
for 120 minutes 
after meal.  
Plasma glucose 
and insulin.  
Significantly lower glycaemic response after PSI 
compared with fructose.  




Japan Healthy subjects 
(three trials, 
n=6, n=14,  
n=10)
Randomized
,  controlled 
single-blind 
crossover
RSS 0, 30 or 50% 




Half of sucrose in 
drink (n=6) or 
food (n=14) 
replaced with 
RSS, or 0, 30 or 
50% sucrose 
replaced with RSS 
in test drink 
(n=10).  Blood 
collected at 5 
time-points 
before and after 
ingestion.    
iAUC for plasma 
glucose and 
insulin.  
All foods and drinks containing RSS showed 
significantly reduced iAUC for glucose compared to 
sucrose control.  No significant changes in iAUC for 
insulin were observed.  
 
33 Kwak et 
al., 2013









TAG 5g, single 
dose before 
meal






(356kcal, of which 
59.57% - 53g - 
was CHO).  Blood 
taken every 30 
mins for 120 mins  
Plasma glucose 
and insulin.  
In subjects with hyperglycaemia, TAG significantly 
reduced AUC for glucose (4% decrease) and plasma 
glucose at 120 mins compared to placebo.  With 
high dose TAG in healthy subjects there was a non-
significant reduction in blood glucose, and 










single blind  
crossover
RSS 0-35g single 
dose
50g tolerance 
test: 50g sucrose 
replaced with RSS 
in ratio 0:10, 3:7, 
5:5, 7:3.  10g 
tolerance test: 
Blood glucose 
and insulin.  
AUC for glucose 
and insulin.  
Significant reductions in AUC for glucose were seen 
with RSS:sucrose in ratios of 5:5 and 7:3.  
Significant  reductions in AUC for insulin were seen 
with ratios of 3:7, 5:5 and 7:3. 
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10g sucrose or 5g 
RSS with 5g 
sucrose.  Blood 
glucose and 
insulin measured.  










PSI 0, 1.8, 3.6 or 
12.5g single 





chocolate and at 
1, 2, 4 and 6hours 
afterwards.  
Free fatty acids, 
blood glucose 
and insulin and 
GLP-1 
measured.  
Post-prandial free fatty acids were increased and 
glucose and insulin decreased after consuming 
chocolate containing PSI compared to placebo.  
Enhanced GLP-1 secretion observed after PSI 
intake.  













PSI 4g or 7g, 2x 
daily for 12 
weeks.  
Placebo 
(sucralose) or PSI 
given 2x daily 










and lipids.    
With PSI: significantly lower body fat percentage, 
body fat mass and BMI.  Significantly lower total fat 
area, particularly subcutaneous fat, in high-dose 
PSI group compared to placebo.  
No significant differences observed in plasma lipids, 
fasting blood glucose, HbA1c or leptin.  
37 Donner et 
al., 2010
USA Subjects (n=8, 




Age 50.7 +/- 
10.9yrs







TAG 15g, 3x daily 
for 14 
months.  
TAG taken with 
regular, non-
standardised 
meals.  Body 
weight and vital 
signs recorded 
and blood taken 
every 2 months.  
Subjects 
questioned about 






Significant weight loss compared to baseline after 
12 months (p=0.01).  
Significant overall decrease in glycated 
haemoglobin, but this was non-significant when 
two patients who had started or increased 
medication were excluded.  
Significant increases in HDL-cholesterol, no changes 
in plasma triglycerides, total cholesterol or LDL-
cholesterol.  All subjects experienced transient mild 
GI symptoms in the first two weeks, these were 
persistent in one subject.  










TAG 2.5, 5 or 





HbA1c , fasting 
blood glucose 
Treatment success (defined as a 0.5 or greater 
decrease in %HbA1c) was greatest for 7.5g dose, 
but difference between doses was not statistically 
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with diet and 
exercise only.  
Majority male, 










three groups and 
given TAG 3x daily 
for 6 months.  
Medical 
examination at 
start and end of 
trial, regular 
blood tests.  
and insulin, 
serum lipids, 
body weight.  
significant.  Only 7.5g dose reduced fasting blood 
glucose after 6 months.  Plasma triglyceride 
increased in 5.0g group, but no significant 
differences in total, LDL or HDL cholesterol.  
Dose-dependent reduction in body weight 
observed.    





Age 42 +/- 
2.7yrs















daily for 12 
weeks





day.  Body weight, 




taken after 0, 2, 4, 
8 and 12 weeks.  
BMI, body fat 





lipids, leptin and 
other 
biochemical 
parameters.   
With RSS, hip circumference was significantly 
reduced compared to baseline after 4 weeks.  Body 
weight BMI, body fat ratio and waist circumference 
were significantly reduced compared to baseline 
from week 8, however differences between RSS 
and HFCS groups were non-significant.  
Retinol-binding protein (highly expressed in visceral 
fat) significantly reduced in RSS group at week 12 
compared to baseline, and leptin significantly 
increased in RSS group at week 12 compared to 
baseline.  







with diet and 

















two groups and 
given TAG or 
placebo (Splenda) 
3x daily before 
meals.  Medical 
examination on 
initial visit, blood 
taken every 2 
months.  
Reduction in 




body weight.  
Significantly greater reduction in HbA1c observed 
in TAG group compared to placebo.  Significant 
difference was seen earlier in the subgroup with 
baseline HbA1c <7.5%.  Effect of lowering HbA1c 
was more pronounced in US population versus 
Indian population.  
No observed effect of TAG on changes in body 
weight or BMI compared to placebo.  
TAG group showed better reductions in total 
cholesterol and LDL compared to placebo from 4 
months.  
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52 Wu et al., 
2012






















sucralose, 20 min 
before meal 
(potato, glucose 
and egg yolk 
labelled with 13C 
octanoic acid).  
Breath samples 
and blood taken 




and GIP, gastric 
emptying.  
Glucose preload increased blood glucose 
immediately and iAUC for glucose was significantly 
higher at 30 mins after the meal, but there were no 
significant differences in iAUC for glucose over 240 
mins.  iAUC for insulin was significantly higher with 
glucose preload over 240min.  No significant 
differences were observed between TIM and 
sucralose in terms of blood glucose or insulin iAUC. 
Plasma GLP-1 was significantly higher with glucose, 
OMG and TIM preloads than with sucralose.  
Plasma GIP was significantly higher with glucose 
and OMG preloads than with sucralose or TIM.  
Gastric emptying was slower with OMG and TIM 
preloads than with sucralose preload.  Fullness 
after meal was reduced with sucralose.  
Nonnutrient substrates of SGLT1 or poorly 
absorbed sweeteners (TIM) could be used instead 
of protein or fat preloads to stimulate GLP-1 and 
slow gastric emptying, therefore reduce post-
prandial elevation in blood glucose in people with 
T2D.  
53 Van Opstal 
et al., 2019





































No significant differences in visual analogue scores 
between sweeteners.  
Glucose and fructose decreased blood oxygen level 
dependent signal, and glucose increased eigen 
vector centrality throughout brain but decreased 
eigen vector centrality in mid-brain.  
PSI and sucralose had no effect on blood oxygen 
level dependent signal, but sucralose increased 
eigen vector centrality in some brain regions.  
The brain reward and satiety responses to low-
calorie sweeteners was minimal compared to 
glucose and fructose.  
Page 60 of 64
Cambridge University Press
British Journal of Nutrition
For Review Only
measure hunger 
























fructose or PSI (6 
visits 1 week 
apart).  






(Cmax) of glucose 
and insulin.  
iAUC for glucose (mmol/L*min) was reduced but 
effect was not significant.  
5g PSI: -35 +/-22 (p=0.11).  
10g PSI: -23 +/-22 (p=0.30)
Pooled PSI: -29=+/-16 (p=0.07) 
No significant effect of PSI on iAUC for insulin, or 
Cmax for glucose or insulin.  Direction and 
magnitude of lowering of glycaemic response was 
similar to previous studies, but not significant 
because of high within-subject variability.  





Age 35.7 +/-2yrs 





PSI 5g, single 
dose before 
meal
5g PSI or 10mg 
aspartame given 
30 min before 
standard meal 






REE, CEE and 




No significant differences in REE.  AUC for FEE 
increased and CEE reduced with PSI compared to 
control.  With PSI, plasma glucose significantly 
reduced at 90 minutes, plasma free fatty acids 
significantly increased from 180 minutes.  




Japan Healthy Asian 
subjects (n=20) 











Subjects visited at 
intervals of 









PSI dose-dependently reduced the elevation of 
blood glucose and insulin after maltodextrin load, 
with significant effects at doses of 5g or greater.  
7.5g PSI administered alone did not affect blood 
glucose or insulin.  
75 Han et al., 
2018








Max single dose 
for occasional 
Maximum single dose with no reports of severe GI 
symptoms was 0.4g per kg body weight.  
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over 1 week.  
daily dose over 6 
weeks with 1-
week washout to 







frequency over 1 
week to find max 
daily dose for 
regular ingestion.  
ingestion, max 
daily dose for 
regular 
consumption.  
Maximum total daily intake for regular 
consumption with no reports of severe GI 
symptoms was 0.9g per kg body weight per day.  
89 Little et al., 
2010
UK Healthy subjects 
(n=31) 16m, 15f, 
age 32.5 
(SEM4.2), BMI 
23.2 (SEM 0.7) 
Single-blind, 
randomised.  























At 22.5g dose (250mOsmol) TAG slowed gastric 
emptying, with no difference between glucose, 
fructose and water.  At 45g dose (500mOsmol), 
glucose, fructose and TAG all slowed gastric 
emptying compared to water, with no differences 
between different hexoses.  This effect was 
reduced when a CCK1 inhibitor was administered.  
Gut-brain signalling affecting gastric emptying 
involves hexose-specific effects, independent of 
osmolality.  TAG seems to slow gastric emptying 
more than other hexoses at physiological 
osmolalities.  
All reported differences are significant unless stated otherwise.  PSI: D-psicose, TAG: D-tagatose, RSS: rare sugar syrup, HFCS: high-fructose corn syrup, TIM: 
TAG-isomalt mixture, OMG: O-methylglucose, T2D: type 2 diabetes, OHAs: oral hypoglycaemic agents, OGTT: oral glucose tolerance test, AUC: area under 
curve, BMI: body mass index, CHO: carbohydrate, HDL: high density lipoprotein, LDL: low density lipoprotein, HbA1c: glycated haemoglobin, GI: 
gastrointestinal, REE: resting energy expenditure, CEE: CHO energy expenditure, FEE: fat energy expenditure, RQ: respiratory quotient, GLP-1: glucagon-like 
peptide-1, GIP: gastric inhibitory polypeptide, SGLT1: sodium-glucose cotransporter 1.  
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Articles identified through database 
searching:  
• Scopus 123
• Web of Science       613
• PubMed 425
671 articles







• Referring only to non-mammalian 
organisms
• Concerned only with synthesis
Abstract screening
71 articles excluded:
• Not nutrition based, including in vitro
only studies
• Not primary research
• Conference proceedi gs




• Type and quantity of rare sugar 
unclear 
• Rare sugar not orally administered
• Paper retracted
46 articles read in full
89 articles
Rare sugar PSI TAG SOR RSS ALL Total
Number of animal studies 24 6 3 3 2 36
Number of human studies 10 6 0 3 0 19
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elevation of blood 
glucose (P, T, p, s)
 fasting blood 
glucose (T, p)
 HbA1c level (T)
 activity of enzymes 
involved in lipogenesis 
(p)
 activity of enzymes 
involved in beta oxidation 
(p)
 expression of 
proinflammatory cytokines 
(t)




 body fat 
percentage 
(P, p, t)







 body weight 
(P, R, T, p, r)
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